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Abstract 
 
Introduction: The current understanding of the significance of circulating pathogen 
DNA in infection is limited. Blood cultures are the current gold standard for pathogen 
detection. The administration of antibiotics can confound pathogen detection by blood 
cultures. Polymerase chain reaction assays of circulating pathogen DNA has the 
potential ability for rapid diagnosis of infection and may be potentially useful in a 
clinical setting. However, the use of this technology has only recently been used in the 
study of sepsis.  
 
Animal models for the study of sepsis have added to our understanding. The failure to 
translate results from animals to humans has been attributed to the disease 
characteristics of sepsis (complexity and heterogeneity), inappropriate clinical trials 
(study of ineffective drugs, inadequate clinical trial designs), and animal models that do 
not fully mimic human sepsis. Therefore, the finding of an easily reproducible in vivo 
human model for pathogenaemia may provide a platform for exploring the host’s 
immune response to circulating pathogen material.  
 
Infection and urosepsis are common complications in diagnostic and therapeutic 
urological procedures. Urological interventional procedures for the removal of renal 
stones are commonly done in a controlled operating environment and may potentially 
be an in vivo model for investigating the host immune response to detected pathogen. 
Antibiotic prophylaxis is routinely given across the world for these urological 
procedures even though the evidence for their use is weak. If the presence of pathogen 
is seen to generate an immune response in these in vivo human models, it could be 
argued that there may be a potential benefit to antibiotic prophylaxis. 
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Aim: To investigate interventional urological stone removal as a model of 
pathogenaemia in man and, therefore, test the following hypotheses: 
1. The detection of circulating pathogen DNA by SeptiFast® PCR is an indicator 
for the infection associated with urological procedures. 
2. The presence of circulating pathogen DNA correlates with the host immune and 
physiological response, supporting the notion that antibiotics prophylaxis is 
important in urological procedures. 
 
Method: In a prospective group of patients undergoing stone removal, blood samples 
were taken at five time points, peri-operatively to assess: 
 
 The presence of pathogen by blood culture and pathogen DNA by SeptiFast® PCR; 
 
 Circulating IL - 6 and IL - 10 levels to assess activation of host inflammatory 
response. 
 
Routine peri - operative observations were recorded throughout as measures of 
physiological responses. 
 
Results: Collected historical data on urological procedures by Salford Royal 
Foundation Trust urology services show that the SeptiFast
®
 assay gave full coverage for 
pathogens seen in this clinical setting. While positive blood culture was rare, 50% of 
patients tested positive for pathogen DNAemia and this was associated with increased 
circulating IL-6 compared to patients with no circulating pathogen DNA. Linkage 
between pathogen DNA positivity and patient outcome was not established. 
 
Conclusion: These data provide novel evidence that pathogen DNAemia is a common 
feature of routine urological procedures correlating with an increased systemic 
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inflammatory response. Endourological stone removal interventions may be a useful 
model for understanding the role of pathogen DNA in triggering inflammatory 
responses to infection in man.  
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Background 
 
Sepsis is one of the oldest syndromes in medicine. Sepsis has been described in literature 
since the days of the ancient Greeks. Sepsis is still one of the top 10 causes of death today. 
The clinical manifestations of sepsis are highly variable, depending on the initial site of 
infection, the causative organism, the pattern of acute organ dysfunction, the underlying 
health status of the patient, and the interval before the initiation of treatment (Angus et al, 
2013). The 'Surviving Sepsis Campaign' has been instrumental in providing the nomenclature 
to help physicians understand the pathophysiology of sepsis (Dellinger et al, 2008). 
The interaction of infection and immune response plays a decisive role in the pathogenesis of 
sepsis. Animal and human studies in sepsis have furthered our understanding on the effect of 
pathogenaemia in sepsis, such as the role of pathogen – associated molecules pattern (PAMP) 
in the host response in sepsis. The significance of circulating pathogen DNA, a recognised 
PAMP, in the infection and sepsis process has not been fully defined in these studies. The 
advancement in nucleic acid technology (NAT) could potentially provide techniques to 
explore the role of pathogen DNA in the host response in sepsis. The aim of this proof of 
concept study was to explore the feasible use of a novel in vivo human model of 
pathogenaemia using microbiological, immunochemistry and NAT techniques.  
Pathogens, infection and sepsis: A relationship explored 
Infection is the invasion and multiplication of pathogens, such as bacteria, viruses, and fungi. 
If pathogen in blood is present, this represents progression of the infection to pathogenaemia. 
Patients’ responses to pathogenaemia differ and there is no clear answer to why some 
individuals show only minor symptoms and others progress to a life threatening state of 
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sepsis (Rao et al, 1991, Mancini et al, 2010). Sepsis is defined as a suspected or proven 
infection plus a systemic inflammatory response syndrome (e.g. fever, tachycardia, 
tachypnoea, and leucocytosis) (Bone et al, 1992) Severe sepsis is defined as sepsis with organ 
dysfunction (hypotension, hypoxemia, oliguria, metabolic acidosis, thrombocytopenia, or 
obtundation). Septic shock is defined as severe sepsis with hypotension, despite adequate 
fluid resuscitation. 
 Septic shock and multiorgan dysfunction are the most common causes of death in patients 
with sepsis. The mortality rates associated with severe sepsis and septic shock are 25 to 30% 
and 40 to 70%, respectively (Angus et al 2001, Vincent et al, 2006). There is an estimated 
annual mortality of between 30 and 50 deaths per population of 100, 000. In Europe alone, an 
estimated 135,000 patients die each year of sepsis – associated complications, with an overall 
incidence of sepsis of three cases per 1000 individuals (Lever et al, 2007). In the US, the 
calculated cost of sepsis is close to 20 billion pounds and is the most common cause of in 
hospital mortality (Lagu, 2012). 
There has been a strong international drive to provide guidelines for clinicians caring for a 
patient with severe sepsis and septic shock. The on-going motivation for the international 
drive is that severe sepsis and septic shock are major health care problems, affecting millions 
of people around the world each year, killing one in four (and often more), and increasing in 
incidence (Dellinger et al, 2013). In 2004, the surviving sepsis campaign, an international 
collaboration of professional societies involved in critical care, treatment of infectious 
diseases and emergency medicine, published the first internationally accepted guidelines to 
improve outcomes for this group of patients (Dellinger et al, 2008). Although controversially 
associated with potential conflicts of interest with the drug industry, it served as a nidus for 
future transparency and guidance in a complex field of medical practice. The following table 
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(Table 1) highlights the diagnostic criteria for sepsis, severe sepsis and septic shock derived 
from this group.  
Table 1 - Diagnostic criteria for sepsis according to the International Sepsis Definitions Conference  
(Levy et al, 2003). 
Sepsis (documented or suspected infection plus ≥1 of the following)† 
General variables 
Fever (core temperature, >38.3°C) 
Hypothermia (core temperature, <36°C) 
Elevated heart rate (>90 beats per min or >2 SD above the upper limit of the normal range for age) 
Tachypnoea 
Altered mental status 
Substantial oedema or positive fluid balance (>20 ml/kg of body weight over a 24-hr period) 
Hyperglycaemia (plasma glucose, >120 mg/dl [6.7 mmol/litre]) in the absence of diabetes 
 
Inflammatory variables 
Leucocytosis (white-cell count, >12,000/mm3) 
Leukopenia (white-cell count, <4000/mm3) 
Normal white-cell count with >10% immature forms 
Elevated plasma C-reactive protein (>2 SD above the upper limit of the normal range) 
Elevated plasma procalcitonin (>2 SD above the upper limit of the normal range) 
 
Hemodynamic variables 
Arterial hypotension (systolic pressure, <90 mm Hg; mean arterial pressure, <70 mm Hg; or decrease in systolic pressure of 
>40 mm Hg in adults or to >2 SD below the lower limit of the normal range for age) 
Elevated mixed venous oxygen saturation (>70%) 
Elevated cardiac index (>3.5 litres/min/square meter of body-surface area) 
 
Organ-dysfunction variables 
Arterial hypoxemia (ratio of the partial pressure of arterial oxygen to the fraction of inspired oxygen, <300) 
Acute oliguria (urine output, <0.5 ml/kg/hr or 45 ml/hr for at least 2 hr) 
Increase in creatinine level of >0.5 mg/dl (>44 μmol/litre) 
Coagulation abnormalities (international normalized ratio, >1.5; or activated partial-thromboplastin time, >60 sec) 
Paralytic ileus (absence of bowel sounds) 
Thrombocytopenia (platelet count, <100,000/mm3) 
Hyperbilirubinemia (plasma total bilirubin, >4 mg/dl [68 μmol/litre]) 
 
Tissue-perfusion variables 
Hyperlactataemia (lactate, >1 mmol/litre) 
Decreased capillary refill or mottling 
 
Severe sepsis (sepsis plus organ dysfunction) 
Septic shock (sepsis plus either hypotension [refractory to intravenous fluids] or hyperlactataemia) 
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These definitions give a coherent language to discuss the parameters seen in sepsis which is 
used globally (Levy et al, 2003). A revised and updated edition of ‘Surviving Sepsis 
Campaign: International Guidelines for management of severe sepsis and shock: 2012’ was 
officially released at the Society of Critical Medicine’s (SCC) 42nd Congress (Dellinger et al, 
2013), including full disclosures of potential conflicts of interest of the authors. It has been 
proposed that the host response to pathogenaemia must play a vital defining role in the septic 
response. To further our understanding on the pathophysiology of sepsis, an in vivo model of 
human pathogenaemia could prove beneficial. 
Sepsis: a pathophysiological response to pathogenaemia 
 
Sepsis is the culmination of complex interactions between the infecting microorganism and 
the host immune, inflammatory, and coagulation responses (James et al, 2006). In the last 10 
years, current knowledge of the host’s ability to recognise a pathogen has increased. The 
expression of common structures known as pathogen – associated molecules pattern (PAMP) 
are thought to be central to the host response in sepsis (Christaki et al, 2011). These 
molecules have the potential to trigger a series of events via the immune system giving us the 
signs and symptoms seen in sepsis and septic shock. 
Examples of PAMPs are:  
 Lipopolysaccharide (LPS); 
 Endotoxins – typically expressed by Gram negative bacteria; 
 Peptidoglycans; 
 Lipoprotein; 
 Flagellin; 
 Bacterial DNA; 
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The use of nucleic acid based diagnostic technology (NAT) such as polymerase chain 
reaction (PCR) assays has prompted significant interest in the role of bacterial DNA as 
PAMP. NAT could potentially have clinical significance as a modern day technique for 
pathogen detection and in the future supplement or even supersede blood cultures in the 
management of infections and sepsis. 
In a recent review (Doi et al, 2009), the course of human sepsis is described as being likely to 
have an initial pro-inflammatory burst responsible for hypotension and organ dysfunction, 
followed by a compensatory anti-inflammatory immune response that leads to an 
immunocompromised state often called immune depression or immune dysfunction. 
Figure 1 -Simplified clinical course of sepsis (Doi et al, 2009) 
 
 
 
Figure  1. Progression of disease is complex, non-linear and varies from one patient to the 
next. Shown is an outline of selected landmark events and processes that appear to be 
common among patients and some animal models. 
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Although the progression of disease is complex and varies individually, from patient to 
patient, there are a few common pivotal events seen in all septic patients. A frequent feature 
in septic shock is a hyper dynamic circulation associated with diminished myocardial 
function. Blood volume is continually lost into the interstitial space of tissue and intracellular 
locations, and blood vessels become blocked by dysfunctional coagulation cascades 
(disseminated intravascular coagulation). Infectious disease, septicaemia in particular, is the 
most common clinical condition associated with disseminated intravascular coagulation 
(DIC). Although, virtually all microorganisms can cause DIC, bacterial infection is most 
frequently related to the development of the syndrome. Clinically onset DIC may occur in 30 
to 50 percent of patients with gram negative sepsis (Levi et al, 1999). The mechanism of DIC 
starts with the systemic activation of coagulation and leads to widespread intravascular 
deposition of fibrin. Additionally, there is a depletion of platelets and coagulation factors. As 
a result, thrombosis of small and mid-size vessels may occur, contributing to organ failure 
and may lead to significant bleeding. Eventually, systolic hypotension and diffuse 
vasoconstriction lead to a fatal, therapy-refractory ischemia of multiple organs and to organ 
necrosis (Kruttgen et al, 2012). 
It should be emphasized that the pro–inflammatory and anti–inflammatory 'stages' are not a 
fixed sequence of events, nor is there an intermediate dissecting point in this diphasic 
process. Inflammatory responses in sepsis are complex, dynamically evolving, pleiotropic, 
synergistic and mutually reinforcing (Christaki et al, 2011). In this thesis, most of our work is 
concerned with analysis of the pro-inflammatory stage/early stage of the host response to a 
pathogen. In the next section, we will discuss the basis of most of the research into the 
pathophysiology of sepsis through animal and human models of sepsis.  
Previous in vivo Models of Sepsis 
 
Animal models of sepsis can be divided into three categories: 
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 Injection of an exogenous toxin such as lipopolysaccharide; 
 Alteration of animal’s endogenous protective barrier such as intestinal leaks; 
 Infusion or instillation of exogenous bacteria. 
Animal studies initially gave credence to the theory that death from sepsis may be due to an 
overstimulated immune system. A number of animal studies have used large doses of 
endotoxin or bacteria, leading to situations where circulating levels of cytokines, such as 
tumour necrosis factor, were exponentially higher in animals than they are in patients with 
sepsis (Hotchkiss et al, 2003).  
LPS infusion/ injection model has been widely used for sepsis research. LPS administration 
induces systemic inflammation that mimics many of the initial clinical features of sepsis, 
including increases in pro-inflammatory cytokines such as TNFA and IL-1, but without 
bacteraemia (Witcherman et al, 1980, Remick et al, 2000, Michie et al, 1988). These results 
prompt work into possible therapeutic interventions. Treatment of LPS-injected animals with 
neutralizing antibody against TNFA or IL-1 resulted in improved outcomes for this model 
(Tracey et al, 1987, McNamara et al, 1993). The most commonly used animal models of 
sepsis in the last 10 - 20 years have been models which alter the animal's endogenous 
protective barrier, such as intestinal leak. Caecal ligation and puncture is very straightforward 
and is the most popular technique used. CLP-induced sepsis models show a cytokine profile 
similar to that in human sepsis (Remick et al, 2000, Eskandari et al, 1992), and anti–TNFA 
treatment fails to alleviate sepsis in CLP models as in human sepsis (Eskandari et al, 1992). 
CLP-induced sepsis increased lymphocyte apoptosis, which mimics immunosuppression at 
the later phase of human sepsis (Ayala et al, 1996, Dear et al, 2006). In this respect, CLP-
induced sepsis is completely different from LPS-induced sepsis and more closely mimics 
human sepsis. There has been a great deal of disappointment in the inability to extrapolate 
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these findings to address sepsis in man. A major drawback with animal models is their 
inability to reflect the complex clinical picture seen in humans. There are clear differences 
between laboratory animals and patients. Mice and rats are housed in specific pathogen-free 
areas, may often be inbred strains, have the same age and weight, and most importantly, do 
not have comorbidities (such as diabetes, hypertension, and pre-existing immunosuppression 
among others) seen in septic humans. Most humans with sepsis are >50 years old, and most 
mice used in sepsis are <3 months old (with an average lifespan of 24 months). Furthermore, 
the experimental models have a precisely known time period. In contrast, we encounter 
patients of different ethnicities, ages, and weight, and most of the time, we are uncertain 
when the symptoms first emerged. In addition, there are differences between rodents and 
humans on the molecular level (Rittirsch et al, 2007). The predominant source of infection in 
septic patients before the late 1980s was Gram negative bacteraemia. Lipopolysaccharide 
(LPS), the main component of gram negative bacterial cell wall, was known to stimulate the 
release of inflammatory mediators from various cell types and induce acute infection 
symptoms in animals (Riedemann et al, 2003). 
Administration of Gram negative bacterial LPS has been used as a model of severe infection 
in man and has been shown to reliably induce a febrile systemic inflammatory response with 
associated hormonal and cytokine changes (Agwunobi et al, 2000). Michie et al (Michie et al, 
1988) measured plasma concentrations of circulating tumour necrosis factor alpha 
(cachectin), interleukin-1 beta, and gamma interferon, together with physiologic and 
hormonal responses, in 13 healthy men after intravenous administration of Escherichia coli 
endotoxin (4ng per kilogram of body weight) and during a control period of saline 
administration. The group showed high levels of plasma concentrations of circulating TNFA 
after the infusion. Results such as these, along with animal studies, prompted the 
investigation of anti – TNFA and anti-LPS interventions as possible treatments in those with 
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sepsis but further studies have not shown this. There are a number of plausible explanations 
for the perceived failure in sepsis trials (Table 2). 
Table 2  Possible reasons for failure in sepsis trials (Riedemann et al, 2003) 
 
Development of sepsis model theory Possible reason for failure 
Assumptions 
1. Gram negative bacteria are cause of sepsis  
2. Bacteria causing disease shed LPS 
3.High levels of serum LPS achieved in 
septic patients 
 
1. Incorrect assumptions based on initiating 
factors of disease 
2. Incomplete clinical observation  
Observation in animals 
1. High level of TNFA achieved following 
LPS infusion 
 
1. Unsuitable animal not translatable to 
humans 
2. High serum level of TNFA not achieved in 
humans during sepsis 
Observation of intervention 
1. Anti - TNFA antibodies increase survival  
 
1. Unable to block all TNFA 
2. Results incorrect 
Clinical trials in humans in sepsis 
1. Anti - TNFA antibodies not protective 
 
1. Anti - TNFA antibodies not protective 
2.Study design insufficient  
3.Sepsis definition insufficient  
4. Drug not working (not tested, etc.) 
5. Wrong dose, time point, etc 
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However, LPS injection in humans is a valid model of endotoxemia and has been used as a 
model to review stress responses and metabolic response seen in human subjects (Agwunobi 
et al, 2000). For this thesis, it is proposed that urological interventional procedures involving 
instrumentation could be a novel in vivo model of pathogenaemia in man and provide an 
easily reproducible model assessing the host immune response to presence of pathogen.    
Model of investigation 
Introduction 
 
Urology is a surgical speciality which has seen marked changes in the last few decades. 
Surgical procedures have moved significantly from open to endoscopic and laparoscopic 
procedures (Bootsma et al, 2008). However, it is well established in the field of urology that 
there are significant levels of bacteraemia after invasive urological procedures. In one study 
of 300 patients (Sullivan et al, 1972) the incidence of bacteraemia after urethral dilatation 
without antibiotic prophylaxis was 24%. It is well known that in urological interventions such 
as cystoscopy, ureteroscopy and percutaneous nephrolithotomy, the rate of positive blood 
cultures detected up to 15% (Christanio et al, 2000, Knopf et al, 2003, Doğan et al, 2002 
Turan et al, 2006, Rao et al 1991). The incidence of septic shock after endoscopic 
manipulation for renal stones was about 1% but ‘less serious effects’ were more common 
(Rao et al 1991). A recent study (Sohn et al, 2013) retrospectively reviewed the medical notes 
of 531 patients who underwent ureteroscopy and ureteroscopic lithotripsy in their hospital 
over a nine year period. A total of 20 patients (3.8%) contracted infectious complications 
after various procedures in the upper urinary tract. The studies above have all been put 
forward as evidence for the perceived benefit of prophylactic antibiotics before urological 
procedures. It is thought the use of prophylactic antibiotics will limit post operation infection 
and urosepsis, which is seen as a common complication of these procedures.  
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One of the most common urological interventions is the removal of renal stones stuck in the 
renal tract that cause persistent symptoms. Therefore, more patients have their renal stones 
removed by ureteroscopy with lasering of the stone or percutaneous nephrolithotomy 
(PCNL). In PCNL, one third experience some peri-operative complications, the most 
common being fever secondary to a urinary tract infection (Gutierrez et al, 2013) In two other 
studies looking at infectious complications in PCNL (Michel et al, 2007, Draga et al, 2009) 
21 - 39.8% of patients had a post-operative fever which was transient in most cases. 
However, 0.3 - 9.3% patients developed sepsis. In both studies, prophylactic antibiotics were 
used. Post op fevers are not uncommon and have caused people to suggest that this could be 
an indicator of an early systemic response to infection. Rao et al (Rao et al, 1991) showed 
that even though post-operative fever was seen in 74% of the patients who had PCNL, only 
41% actually had endotoxemia.  
There is a significant burden associated with urosepsis and urinary tract infection. Urinary 
tract infections are the most common cause of hospital associated infections (nosocomial 
infection). Approximately 80% of nosocomial UTI have been found to be associated with 
indwelling urinary catheters.  Genitourinary interventions appear to be the facilitating factor 
in 5 – 10% of nosocomial UTI. Patients who have been exposed to some instrumentation are 
at high risk of urinary tract infections (Turan et al, 2006). In the USA, a study from early 
2000s showed that urinary tract infection accounts for 1 million emergency department visits, 
resulting in 100,000 hospitalizations (Foxman et al, 2003). 
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Endourology 
 
Endourology is the branch of urologic surgery concerned with closed procedures for 
visualizing or manipulating the urinary tract. It has lately grown to include all urological 
minimally invasive surgical procedures. Opposed to open surgery, endourology is performed 
using small cameras and instruments inserted into the urinary tract. For the purpose of this 
thesis, ureteroscopy and PCNL are the endourological procedures used and the indication for 
all of these procedures was for the treatment of renal calculi. 
Renal calculi develop from crystals that separate from urine within the urinary tract. The 
chemical composition of renal stones, typically seen in clinical practice, is highlighted below 
(Figure 2). There are well-recognised predisposing factors for stone formation which include 
dehydration, lifestyle, geographical location (dry arid climate), and certain specific risk 
factors.  
Figure 2 - Percentage of kidney stone types 
 
 
 
Figure 2. This figure shows the most common composition of 
kidney stones. The most common type of kidney stones is 
composed of calcium oxalate in about 75 to 80% of all stones. 
About 10% of all stones are formed from uric acid. 
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These factors may include anatomical / structural abnormalities (e.g. ureteropelvic junction 
obstruction, urinary diversion surgery, horseshoe kidney, calyceal diverticulum), and 
underlying metabolic conditions (e.g. cystinuria, oxaluria, gout), certain drugs, and urease-
producing infective organisms (Tseng et al, 2011). 
Endourology procedure - Ureteroscopy 
 
An ureteroscopy is an examination or procedure using an ureteroscope. An ureteroscope, like 
a cystoscope, is an instrument for examining the inside of the urinary tract. An ureteroscope 
is longer and thinner than a cystoscope and is used to see beyond the bladder into the ureters.  
There are two main types of ureteroscopes (1) flexible like a thin, long straw (2) rigid and 
firm. Through the ureteroscope, the obstructing stone in the ureter can be visualised and then 
removed via a small basket at the end of a wire inserted through an extra channel in the 
ureteroscope. In addition, a separate way to treat urolithiasis through an ureteroscope is to 
extend a flexible fibre through the scope up to the stone and then, with a laser beam shone 
through the fibre, break the stone into smaller pieces that can then pass out of the body in the 
urine. A stent is usually placed to keep ureter patent. 
Endourology procedure - Percutaneous nephrolithotomy (PCNL) 
 
Percutaneous nephrolithotomy is a surgical procedure for removing medium-sized or larger 
renal stones from the patient's urinary tract by means of a nephroscope passed into the kidney 
through a track created in the patient's back via a small puncture wound (up to about 1cm). 
PCNL was first performed in Sweden in 1973 as a less invasive alternative to open surgery 
on the kidneys. The term "percutaneous" means that the procedure is done through the skin. 
Nephrolithotomy is a term formed from two Greek words that mean "kidney" and "removing 
stones by cutting." 
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With a small 1cm incision in the loin, the percutaneous nephrolithotomy (PCNL) needle is 
passed into the pelvis of the kidney. The position of the needle is confirmed by fluoroscopy. 
A guide wire is passed through the needle into the pelvis. The needle is then withdrawn with 
the guide wire still inside the pelvis. Over the guide wire the dilators are passed and a 
working sheath is introduced (Fig 3).  
Figure 3 - PCNL (taken from www.uroinfo.ca) 
 
 
A nephroscope is then passed inside and small stones are taken out. A nephroscope is an 
instrument with a fiberoptic light source and two additional channels for viewing the inside of 
the kidney and irrigating (washing out) the area.  
The surgeon may use a device with a basket on the end to grasp and remove smaller kidney 
stones directly. Larger stones are broken up with an ultrasonic or electro hydraulic probe, or 
via a laser beam. In case the stone is big it may first have to be crushed using ultrasound 
Figure 3. This figure outlines the approach use for stone removal by percutaneous 
nephrolithotomy (PCNL). 
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probes and then have the stone fragments removed. The procedure can take 1 - 2 hours. 
(Wynberg et al, 2012). As mentioned earlier, prophylactic antibiotics are commonly used in 
this procedure and, presently, there is little evidence for their use in the urological procedures 
mentioned in this proof of concept study. It can be postulated that in our novel in vivo mode, 
if there is a relationship between the presence of detected pathogen and a detected host 
response to the pathogen, it could be argued that antibiotic prophylaxis may be beneficial in 
this setting. In the following section, there will be a brief exploration on the current use of 
antibiotic prophylaxis in urological procedures.  
Antibiotic prophylaxis in urology procedures 
 
In urology, the indication for antibiotic prophylactic use is to prevent post-operative 
infections. A pan-European survey was carried out by the EAU Section for Infection in 
Urology (ESIU) in a large number of European countries and found that ≥ 10-12% of patients 
had a healthcare-associated UTI (Bjerklund et al, 2007). The current European Association 
guidelines on peri-operative antibiotic prophylaxis state that there is no evidence for any 
benefits of antibiotic prophylaxis in standard non-complicated endoscopic procedures and 
shockwave lithotripsy (SWL), although it is recommended in complicated procedures and 
patients with identified risk factors. The EAU guidelines reference papers which are 
described later in this introduction (Fourcade et al, 1990, Knopf et al, 2003, Rao et al, 1991).  
Of all urological surgical procedures, there is strong evidence for a role of antibiotic 
prophylaxis in transrectal prostate biopsies and transurethral resection of the prostate 
(Bootsma et al, 2008). However, antibiotic prophylaxis is still widely used with marked 
differences in the regimens and choice of antibiotics used from one urology department to 
another. With different approaches, there is the risk of antimicrobial resistance developing. 
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There are a number of clearly established risk factors for peri-procedural infectious 
complications. These are highlighted in the table below (Table 3) 
 
Table 3  Generally accepted risk factors for infectious complication (Grabe et al 2012) 
 
General risk factors Special risk factors associated with an 
increased bacterial load 
Older age Long pre-operative hospital stay or recent 
hospitalisation 
Deficient nutritional status History of recurrent urogenital infections 
Impaired immune response Surgery involving bowel segment 
Diabetes mellitus Long term drainage 
Smoking  Urinary obstruction  
Extreme weight Urinary stones 
Coexisting infection in a remote site Colonisation with microorganisms 
  
 
A pan-European study on nosocomial UTI (Bjerklund et al, 2007) has identified the three 
most important risk factors for infectious complications as: 
 An indwelling catheter; 
 Previous urogenital infection;  
 Long preoperative hospital stay. 
The risk of infection varies with the type of intervention undertaken. 
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There are few randomised control trials looking at antibiotic prophylaxis in ureteroscopy and 
PNCL procedures. Knopf and his group (Knopf et al, 2003) studied 113 patients undergoing 
uretoscopy for stone removal randomised to a single oral dose of levofloxacin versus no 
antimicrobial. There was a significantly lower incidence of post-operative bacteriuria in those 
who received the prophylactic antibiotic (1 patient [1.8%] vs. 7 patients [12.5%]) (p=0.026)). 
Fourcade and his group (Fourcade et al, 1990) compared placebo with antibiotic prophylaxis 
in both PCNL and ureteroscopy, with separate analysis performed for each intervention 
group. With such small individual groups, no statistical significant difference was seen 
between the groups. 
Given these findings, the evidence for antibiotic prophylaxis is low to moderate in these 
endourological procedures. It is proposed that our proof of concept model will identify 
patients who show a peri-procedural inflammatory response associated with pathogen DNA. 
This is potentially significant as it could be a first step towards developing targeted antibiotic 
prophylaxis for urological procedures. This in turn may have both cost-effectiveness benefits 
and reduce adverse events associated with unnecessary antibiotic use.  
Tools for investigation 
 
In this study to achieve our aims, blood cultures and polymerase chain reaction (PCR) assays 
were used for pathogen and pathogen DNA detection respectively. In order to assess the host 
immune response amongst the study population, serum interleukin 6 (IL-6) and interleukin 10 
(IL - 10) levels were used as markers for the hosts’ immune response. 
Microbiological investigations – Blood Cultures 
 
The current gold standard of bloodstream microbial detection and identification is blood 
culture analysis. Blood culture analysis involves the automatic, continuous monitoring of 
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liquid culture, followed by Gram stain, subculturing and use of phenotypic methods to 
identify the organism and its susceptibilities. With blood culture analysis, it is very important 
to differentiate between the presence of true pathogens in blood compared to detection of 
contaminants. A study of 843 episodes of positive blood cultures in adult inpatients from 
three hospitals in the US suggested that certain organisms should almost always be thought to 
represent true bacteraemia or fungaemia when isolated from a blood culture rather than 
contaminant (Weinstein et al, 1997). These organisms included Staphylococcus aureus, 
Streptococcus pneumoniae, Escherichia coli and other Enterobacteriaceae, Pseudomonas 
aeruginosa, and Candida albicans.  
Certain organisms have been found to represent contamination in a significant proportion of 
cases. These organisms include coagulase-negative staphylococci, Corynebacterium species, 
Bacillus species other than Bacillus anthracis, Propionibacterium acnes, Micrococcus 
species, viridans group streptococci, enterococci, and Clostridium perfringens (Weinstein et 
al, 1997). However, it is crucial to recognize that each of these organisms can also represent 
true bacteraemias with devastating consequences, particularly if untreated due to 
misinterpretation as contaminants (Hall et al, 2006). 
Limitation of blood cultures 
 
Blood cultures have a central role in the detection of blood borne pathogens in patients with 
evidence of a systemic inflammatory response (SIRS). SIRS defines a clinical response to a 
non-specific insult of either infectious or non-infectious (e.g. ischaemia, trauma, 
inflammation). The detection and identification of pathogens defines such patients as being 
septic and along with the clinical presentation would prompt appropriate treatment with 
antimicrobial therapy. However, there are a number of limitations associated with blood 
cultures. 
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1. Timing issues - A major limitation to blood culture is the time required to complete the 
process, which ranges from one to five days or more. (Ecker et al, 2010). After a positive 
signal is given by the automated instrument (usually within 24 to 48 h of incubation), a Gram 
stain is then performed (together with a preliminary evaluation of the antimicrobial 
susceptibility) directly from the blood culture bottle. 
The pathogen is then identified by biochemical tests. Rapid phenotypic tests may allow the 
identification of a large percentage of pathogens commonly recovered from blood cultures 
(usually within 18 to 24 h); however, more time is often needed for the final identification 
and for antimicrobial susceptibility evaluation of a given isolate, especially when slow-
growing pathogens such as yeasts or anaerobes are present (Mancini et al, 2010).  
2. Sensitivity and false positive - Sensitivity of blood cultures for slow-growing and fastidious 
organisms can be poor. Blood cultures miss fastidious organisms that are difficult or 
impossible to culture such as Legionella pneumophilia, Chlamydia pneumoniae, and 
Mycoplasma pneumoniae (Socan et al, 1999).  
The culture diagnosis of invasive fungal infections has low sensitivity and the results are not 
usually available for many days in an important number of cases. From a clinical view point, 
these infections are seen amongst neutropenic patients frequently and mortality from 
untreated infection is high (Peters et al, 2004). Reportedly, more than 50% of blood cultures 
are negative where true bacterial or fungal sepsis is believed to exist (Ecker et al, 2010). In 
addition to this, as many as half of the cultures that are positive, represent contaminants 
organisms inoculated from the skin into culture bottles at the time of sample collection. Such 
results are false-positive blood cultures that can lead to unnecessary investigations and 
treatments.  
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3. Low impact on clinical management - It has been shown that there are a number of medical 
disorders where blood cultures have little influence on clinical management such as non – 
severe community acquired pneumonia and cellulitis (Peters et al 2004). It has been shown 
that the most therapeutic interventions occur immediately after collection of blood samples 
for culture and that the number of intervention decreased rapidly with time (Munson et al, 
2003). 
Blood cultures remain central to care of septic patients; however, molecular techniques aimed 
at complementing and negating the limitations of blood cultures are likely to be pivotal in the 
future, especially for ‘time-critical’ decision making and diagnosis. Polymerase chain 
reaction (PCR) assays of circulating pathogen DNA is seen as a potential technology which 
can be utilised for the rapid detection of infection. 
Molecular investigation – Nucleic acid based diagnostic technology 
Molecular methods based on nucleic acid based diagnostic technology (NAT) have been 
developed for the diagnosis of infection and pathogen identification. Polymerase chain 
reaction (PCR) is an example of a nucleic acid based diagnostic technology (NAT). PCR is a 
biochemical technology in molecular biology, which amplifies a single (or a few copies) of a 
piece of DNA across several orders of magnitude, generating thousands to millions of copies 
of a particular DNA sequence. Several pathogen-specific, broad range, and multiplex PCR-
based amplification strategies have been used for positive blood cultures (Mancini et al, 
2010). An example of a more recent process used for the direct molecular detection of 
pathogens is shown below (Fig 4) 
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 Figure 4 - Identification and genotyping of microbes by PCR/ ESI/ mass (Ecker et al, 
2010) 
 
 
NAT  applied to sepsis and detection of blood borne micro organisms can be divided into two 
main categories which will be discussed next.  
NAT assays for the detection and identification of pathogens from blood culture bottles 
 
In the first main catergory, molecular detection and speciation after an initial growth in blood 
culture medium occurs most easily with either hybridisation based or amplification based 
techniques (Peters et al, 2004). After the initial growth in blood culture medium, the 
hybridisation based technique provides identification of most pathogens within two hours. An 
example is fluorescence in situ hybridization (FISH) with oligonucleotide probes targeting 
Figure 4 – This schematic shows the stepwise processes involved in the identification 
of microorganisms by PCR. ESI – electro spray ionisation 
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bacterial or fungal genes (typically rRNA genes). However, these methods can be technically 
difficult and need advanced detection systems and also require skilled laboratory staff. 
Pathogen-specific assays is limited due to the high variety of pathogens, potentially 
responsible for blood borne infections. The main disadvantage of broad-range approaches are 
that after the PCR amplification of a target sequence, further identification procedures are 
necessary. The broad assay approach could be more useful for persistently negative blood 
cultures in the presence of a strong clinical suspicion of bacteraemia and fungaemia, as in the 
case of infective endocarditis (Mancini et al, 2010). Typically, blood cultures samples are 
taken multiple times for improved detection of organsims which are located in regions with 
little blood supply such as heart valves.  
The risk of false-positive results due to environmental bacterial or fungal DNA contaminaton 
on sampling bloods needs to be considered when these panbacterial or panfungal approaches 
are used (Ng, 2006). The multiplex PCR approach targets different genes of those pathogens 
most frequently isolated from blood stream infections.  
After the amplification process, there is sequencing analysis of the microorganism. The above 
methods of molecular identification of micro organisms on positive blood cultures are not 
routinely practiced in microbiology labs as they do not show greater or parallel clinical 
benefit or cost effectiveness compared with conventional methods (Peters et al, 2004). 
Direct molecular detection of pathogens in blood with PCR 
 
In 1993, two separate groups published the first use of pathogen specific PCR assay to detect 
bacteria in blood. In the first study to be published (Song et al, 1993), a Salmonella typhi 
PCR assays was described. The number of clinical samples was small. However, the 
peripheral mononuclear cells from 11 of 12 patients with typhoid fever confirmed by blood 
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culture were positive for DNA fragment of the flagellin gene of Salmonella typhi, whereas 10 
blood specimens of patients with other febrile diseases were negative. This shows that the 
sensitivity of the PCR assay was 92% compared with blood cultures. In addition, Salmonella 
typhi DNA were detected from blood specimens of four patients with suspected typhoid fever 
on the basis of clinical features but with negative cultures. Interestingly, on the basis of the 
results of the PCR, these patients were treated with ciprofloxacin for 14 days with an 
excellent outcome. 
There are four different molecular diagnostic approaches for detection of bacterial and fungal 
DNA in whole blood samples that are currently approved for clinical use by European 
regulatory authorities (Pletz et al, 2011):- 
 A multiplex real – time PCR that simultaneously detects a pre defined panel of the 
most important sepsis pathogens by species- or genus-specific fluorescent probes (SeptiFast
®
; 
Roche). 
 A eubacterial and panfungal real – time PCR that is able to detect nearly all known 
bacterial and fungal pathogens by a 16S and 18S ribosomal RNA (rRNA) gene-based 
universal PCR followed by sequencing of the amplification product for species identification 
(SepsiTest
TM
; Molzym). The term eubacteria is commonly used to describe 'true bacteria' 
which includes all bacteria except archaebacteria. 
 A multiplex PCR that detects a predefined panel of the most important sepsis 
pathogens by electrophoretic separation of target-specific amplicons. An amplicons is a piece 
of DNA or RNA that is the source and/or product of natural or artificial amplification or 
replication events. (VYOO
®
; SIRS Lab) 
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 A eubacterial and panfungal PCR that is able to detect nearly all known bacterial and 
fungal pathogens by genome – specific targets followed by mass spectrometry for species 
identification (Plex-ID; Abbott). 
The majority of clinical studies which compared PCR based diagnostics with conventional 
blood culture showed that more pathogens were detected by PCR techniques (Pletz et al, 
2011). 
SeptiFast
®
 assay 
 
The Roche product SeptiFast
®
 has been available longer than other molecular-based tests and 
is the assay used in our proof of concept model. SeptiFast
®
 uses real-time PCR in a 
nonquantitative mode to identify ten bacteria at the species level, several more at the genus 
level, as well as five Candida species and Aspergillus fumigatus. This assay reportedly 
identifies the 25 organisms that account for more than 90% of the culturable pathogens 
associated with sepsis (Ecker et al, 2010). No unculturable organisms are identified nor are 
most of the highly fastidious organisms that are difficult to culture. Whilst the majority of 
studies have reported that SeptiFast
®
  has a higher pathogen detection rate compared with 
blood culture analysis (Dierkes et al, 2009, Lehmann et al, 2010, Louie et al, 2008, Mancini 
et al, 2008, Westh et al, 2009), other studies have disputed this (Bloos et al, 2010). 
Furthermore, it has been reported that SeptiFast
®
 is more sensitive in detecting fungal 
pathogens, such as Candida species and Aspergillus fumigatus when compared with 
conventional blood culture (Dierkes et al, 2009, Westh et al, 2009). 
A number of studies have described the occasional incidence of negative PCR results 
associated with a simultaneous positive blood culture, so-called ‘false’ negative results 
(Lehmann et al 2010, Louie et al 2008, Yanagihara et al, 2010). This can occur because the 
aetiologic organism is not found in the SeptiFast
®
 Masterlist (which is an obvious limitation 
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of the assay), or because of a technical fault with the platform not detecting the presence of 
the organism. Low concentration of the organisms in the blood sample can result in a ‘false’ 
negative result due to the limit of detection of SeptiFast
®
 (Yanagihara et al, 2010). Excess 
total DNA in the sample can lead to saturatation to the enzyme which interferes with the 
amplification and signaling to produce a negative result (Louie et al, 2008).  
As SeptiFast
®
 has an analytical sensitivity of 3 to 30 CFU/ml (Lehmann et al, 2008, Pletz et 
al, 2011), the diagnostic capabilities of the assay is limited to some extent, compared with the 
theoretical sensitivity of one CFU per culture bottle in conventional blood culture after 
inoculating approximately 10ml whole blood (Lehmann et al, 2010). This is potentially 
problematic as quantitative blood culture studies have shown that the majority of clinically 
significant bacteraemia in adults are characterised by circulating low numbers of bacteria 
(Lehmann et al, 2010). There have been a number of studies which have looked at the clinical 
application on the SeptiFast
®
 assay in medical practice. Avolio et al (Avolio et al, 2010) 
compared traditional blood cultures with SeptiFast
®
 in patients with suspected blood stream 
infections (BSI) arriving at the emergency department of a regional Italian hospital. In this 
study population, not all pathogens detected by blood cultures were also found by the PCR 
technique used even when those pathogens are on the PCR panel profile. Of 144 blood 
samples examined, 13 cases (24.5%) blood culture identifed organisms which were not 
detected by real time PCR and similar findings have been seen in other studies. 
In Avolio et al’s study (Avolio et al, 2010), the SeptiFast® PCR assay gave positive results 
where the blood culture was negative in 10 cases. In these10 cases there was a microbiology 
confirmation of infection by pathogen isolation from other sites with diagnoses ranging from 
pneumonia (two cases), meningitis (two cases), aortic prosthesis infection (one case), 
necrotising fasciitis (one case), or urosepsis (three cases). Therefore, in this population the 
41 
 
SeptiFast
®
 results positively impacted the therapeutic choices and clinical outcome of the 
patients (Avolio et al, 2010). 
Effect of antimicriobial administration pre testing on both microbiological and 
molecular approaches  
The most recent international guidelines for sepsis (Dellinger et al, 2013), recommend 
obtaining blood cultures before antimicrobial therapy is initiated if such cultures do not 
significantly delay ( >45 minutes) the start of antimicrobial(s) administration. However, a 
substantial number of blood cultures are taken from pretreated patients or patients developing 
sepsis despite antibiotic prophylaxis, i.e. pre–operative or after solid organ transplants. A 
percieved advantage of a DNA based detection system, compared to blood cultures, is that 
the pathogen does not have to be viable at the time of sampling. A Danish study (Westh et al, 
2009), compared SeptiFast
®
 with blood cultures in a multicentre trial of patients with 
suspected bacterial and fungal sepsis. 558 samples from 359 patients were evaluated. The rate 
of positivity was 17% from blood cultures and 26% for SeptiFast
®
. The administration of 
antibiotics did not affect the ability of DNA detection by the SeptiFast
®
 assay and the 
SeptiFast
®
 assay had a better pick up rate for pathogen detection. This study highlights the 
fact that blood culture positivity and pathogen DNA positivity are not equivalent measures of 
infection.  
There are situations where PCR detection occurs in those with negative cultures. It is 
commonly known that our current gold standard for detecting pathogens in blood is blood 
cultures. Blood cultures fail to identify more than 50% of the cases of sepsis, believed to be 
caused by bacteria or fungi based on clinical and other criteria (Ecker et al, 2010). In 
numerous studies, as mentioned previously, SeptiFast
®
consistently identified more positive 
specimens than blood cultures. These potential ‘false positives’ were frequently deemed 
clinically significant based on chart reviews of clinical data, other analytical evidence of 
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infection or disease severity and were often subsequently confirmed after isolation of the 
pathogen from relevant clinical samples from other sources (Ecker et al, 2010). SeptiFast
® 
- 
positive / culture-negative results could conceivably come from non-viable organisms in the 
blood (resulting from ongoing antibiotic treatment), cell-free DNA released from infected or 
colonized remote infection sites, or antibiotic interference with culture. With this variation in 
the potential role of circulating pathogen DNA, at present molecular PCR techniques would 
have a role as an adjunct to blood cultures.  
For the purpose of this proof of concept study, it was vital to choose a method of detecting 
pathogen DNA in this model which would be robust enough to detect the organisms typical 
seen in this study population. It is widely established that the SeptiFast
®
 assay covers the 
majority of bacteria and fungi seen in intensive care patients. It is also important that this 
coverage is broad enough for the urology patient population in this study. At Salford Royal 
Foundation Trust, where the study was undertaken, the urology service maintains a clinical 
database comprising clinical infection and microbiological data on interventional renal stone 
treatment dating from 2004 to 2011. The data establishes that SeptiFast
®
 has suitable 
coverage of microbial detection to make this a viable tool for investigating infection in this 
study population. 
Table 4 summarises the comparative advantages and disadvantages between blood culture 
and molecular methods in identifying blood stream infection (CFU - colony forming unit). 
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Table 4 - Needs and current status of methods to identify bloodstream infections 
(Adapted from Ecker et al, 2010) 
 
 
NEED 
 
CURRENT STATUS 
 
FUTURE 
OPPORTUNITIES 
 Culture Molecular methods Molecular methods 
Identify all bacterial and 
fungal infection 
Identifies only 
culturable 
organisms 
Varies with method 
from 25 frequently 
cultured organisms to 
panbacterial; limited 
or no fungal 
Panbacterial and 
panfungal identification 
High sensitivity: 
bloodstream infections 
can be caused by less 
than 10 CFU/ml in adults 
Blood cultures 
are negative in 
>50% of 
clinically sepsis 
cases 
Mixed results.  
Blood culture is more 
sensitive in some 
cases, but molecular 
methods identify 
organisms missed by 
culture; reported 
sensitivities as low as 
3 CFU/ml 
Mixed results.  
Blood culture is more 
sensitive in some cases, 
but molecular methods 
identify organisms 
missed by culture; 
reported sensitivities as 
low as 3 CFU/ml 
Rapid identification; 
mortality increases hourly 
in the absence of 
appropriate antimicrobial 
therapy 
Requires 1–5 
days 
Requires 1 day < 1 hr 
Antimicrobial resistance 
determination 
Requires 1 
additional day 
after obtaining 
culture isolate 
A few major 
resistance 
determinants 
measured 
Significant opportunity 
with future 
understanding of 
molecular mechanisms 
Quantitative assessment 
of pathogen load; load 
correlates with disease 
severity 
Quantitative 
culture methods 
too difficult for 
routine practice 
Not quantitative Quantitative results 
Low labour requirements,  Labour intensive Labour intensive Fully automated 
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Cytokine driven immune reponses 
The body has developed intricate pathways to protect and defend against pathogenic 
organisms. Cytokines are one of the main protagonists in these processes. Cytokines are 
small cell-signalling protein molecules that are secreted by numerous cells and used 
extensively in intercellular communication. Cytokines can be proteins, peptides, or 
glycoproteins; the term "cytokine" encompasses a large and diverse family of regulators 
produced throughout the body by cells of diverse embryological origin (Kruttgen et al, 2012). 
To understand the role of important cytokines such as IL - 6 and IL - 10, it is important to 
understand the early stages of the host immune response to common pathogens such as 
bacteria and fungi. The expression of common structures, known as PAMP, is thought to be 
central to the host response in sepsis (see earlier). The release and increase in serum 
concentration pro – inflammatory cytokines (cytokine storm) in sepsis has been shown to be 
triggered by release of bacterial endotoxin (Hack, 1989, Krettgen et al, 2012). 
In gram positive sepsis, a similar role is seen with lipoteichoic acid and peptidoglycans 
(Schmidt et al, 2011). Both LPS and lipoteichoic acids bind to members of a family of PAMP 
receptors. These receptors are known as the toll like receptors (TLR). The combination of the 
receptor and its ligand alerts the innate immune response system to presence of invading 
pathogen. The innate immune system comprises the cells and mechanisms that defend the 
host from infection by other organisms in a non-specific manner and is the first line of the 
host's defence . 
TLRs trigger intracellular pathways involving the signaling molecules MyD88 or TRIF and 
leading to activation of the transcription factors c – Jun N – terminal kinase and NF-kB, 
thereby initiating the transcription of pro – inflammatory cytokine genes and production of 
pro – inflammatory cytokines such as interleukin - 6 (IL-6) (Stearns – Kurosawa, 2011). 
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Interleukin 6 
 
IL-6 is a cytokine that acts as both a pro – inflammatory and anti – inflammatory cytokine. 
IL–6 is a cytokine linked to sepsis and is one of the major NF – kB target genes. IL-6 is a 
member of 4 helical cytokine families, which signals via an 80 kDA cytokine receptor (IL – 
6R). Once IL – 6 binds to IL – 6R, the resultant complex associates with the signalling 
receptor subunit gp130. Il – 6 signals by two mechanisms (a) via the ubiquitous trans 
membrane gp130: ‘classic’ signalling using membrane –bound IL – 6R (gp80) and (2) via 
trans-signalling using soluble IL – 6R (sIL – 6R).  
Research has shown that pro – inflammatory activities of IL – 6 are mainly driven by IL – 6 
trans – signalling via the sIL – 6R, whereas anti – inflammatory or regenerative functions rely 
on classic IL – 6 signalling via the membrane bound receptor (Scheller et al, 2011). In a study 
(Waage et al, 1989), serum samples from patients with meningococcal disease were 
examined for the presence of IL - 6, TNFA and LPS. Median serum concentration of IL - 6 
was 1,000 times higher in patients with septic shock (189 ng/ml) than in patients with 
bacteraemia or meningitis alone. This suggests that IL - 6 has an important role in the sepsis 
process. It was concluded that a complex pattern of cytokine exists in patients with fatal 
sepsis in those with meningococcal infection, and that the release of IL - 6 as well as 
interleukin 1 (IL - 1) is associated with a fatal outcome.  
For a number of years, IL - 6 has been established as a prognostic marker for mortality in 
sepsis. In a study (Hack et al, 1989), a group measured levels of IL - 6 in plasma samples 
from 37 patients with sepsis or septic shock obtained at the time of admission to the intensive 
care unit and related these levels to hemodynamic and biochemical parameters as well as to 
clinical outcome. In 32 of the 37 patients, increased levels of IL - 6 were found, occasionally 
up to 7,500 times the normal level (Fig 5).  
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Figure 5 - Il – 6 and sepsis - associated mortality (Hack et al, 1989) 
 
 
 
Importantly, IL - 6 on admission appeared to be of prognostic significance: levels were 
higher in septic patients who subsequently died than in those who survived (P = .0003), 
particularly when only patients with septic shock were considered (P less than .0001). All 
nine septic patients with levels of less than 40 U/mL on admission survived, whereas 89% of 
the nine patients with levels exceeding 7,500 U/mL died.  
Research in the oncology field has raised a possible role for IL – 6 in the hemodynamic 
response typically seen in the sepsis process. IL – 6 trans signalling was found to increase 
endothelial permeability by phosphorylation of VE – cadherin (Kruttgen et al, 2012). This 
process could lead to vascular leakage and may play a vital role in the life threatening 
refractory drop in blood pressure seen in shocked patients. 
Figure 5 – Mortality in 37 patients with sepsis as a function of IL- 6 levels on 
admission. Patients were divided into four groups according to the IL- 6 
levels as indicated 
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Interleukin 10 
 
Interleukin 10 is an anti-inflammatory cytokine. Interleukin 10 levels are in-detectable in 
healthy individuals. The IL – 10 protein is a homodimer; each of its subunits is 178 amino 
acids long, as shown in the figure below (Figure 6).  
Figure 6 – Interleukin 10 and receptor (Kotenko et al, 1997) 
 
 
IL – 10 is a pleiotropic cytokine with important immunoregulatory functions whose actions 
influence activities of many cell types in the immune system (Couper et al, 2008). IL – 10 is 
capable of repressing synthesis of pro-inflammatory cytokines such as TNFA, IL – 2 and 
interferon gamma made by macrophages and regulatory T – cells.  
Figure 6 – This figure shows diagramatically the structure of IL – 10 and IL – 10 receptor and 
the subsequent intercellular signalling from their interaction 
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IL-10 has the ability to suppress the antigen presentation capacity of antigen presenting cells 
as well. Conversely, IL – 10 stimulates a number of inflammatory cells as well. IL – 10 has 
been seen to be elevated in the state of sepsis with an association between its concentration, 
severity of sepsis and death (Friedman et al, 1997, Giannodous et al, 2000). 
Summary 
Sepsis is the leading cause of death in critically ill patients. Sepsis has been described in 
medical literature for over 2000 years but is still a leading cause of both economic burden and 
patient morbidity and mortality. All episodes of sepsis are associated with infection and the 
presence of pathogen in body tissue. The complex interaction between pathogen and the host 
response has been extensively investigated for decades. However, the role of circulating 
pathogen DNA in the early triggering of the host response to infection is not understood fully. 
Blood culture is the current gold standard method for pathogen detection in blood but cannot 
provide time – critical results that impact on the initial management of a patient (Dark et al, 
2009). In addition, this method of pathogen detection is particularly susceptible to false 
negative results following antimicrobial use. Molecular methods like PCR have the potential 
ability to rapidly detect (or rule out) the presence of illness causing organisms. These 
molecular methods could facilitate effective immediate management of the infection and 
influence the subsequent clinical outcome. These molecular methods are not influenced by 
antibiotic use. However, this expensive technology has a number of limitations.  
In recent years, urology as a surgical speciality has moved away from open surgery, towards 
endourological procedures for the treatment of renal stones. As with any procedure, these 
interventions are not without complications. One of the most commonly seen complications 
is infection and urosepsis. To combat this complication, it is common practice to give 
prophylactic antibiotics. There is a long established association between bacteraemia and 
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invasive instrumentation during urological procedures. However, there is no clear evidence 
on the use of prophylactic antibiotics in all urological procedures, particularly not on those 
commonly used in stone removal. 
Therefore, in this thesis, it is proposed that interventional urological stone removal can be a 
model to establish if the detection of pathogen by PCR is an indicator for infection in man. In 
this clinical setting, we can explore the patient's physiological response (peri-operative 
observations) and immune response (serum IL - 6 and IL-10 levels) in those who have 
pathogen detected by blood culture and more importantly, PCR assay. The PCR assay used in 
this study was the SeptiFast
®
 assay. SeptiFast
®
 is a multiplex RT - PCR assay that has a 
broad detection coverage of the 25 most commonly detected pathogens in critically ill 
patients seen in intensive care settings.  
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Aim of study 
To appraise the presence and significance of blood borne microorganisms that may appear in 
patients during interventional urological procedure involving urinary tract instrumentation 
with:- 
1. A multiplex real – time PCR that simultaneously detects a pre-defined panel of the most 
important sepsis pathogens by species- or genus-specific fluorescent probes (SeptiFast
®
; 
Roche); 
2. Blood cultures. 
To appraise the host immune responses and clinical relevance of urological interventional 
procedures as a model of human pathogenaemia by:- 
1. Measuring the serum levels of IL - 6 and IL – 10 at five time points; 
2. Measurements of patient clinical observation both pre, during and after procedure. 
To help understand the significance of the presence of antibiotics in the laboratory detection 
of microorganisms using the complementary techniques of culture and microorganism DNA 
or RNA analysis. 
The hypotheses being tested were, therefore, that:  
1. The detection of circulating pathogen DNA by SeptiFast
®
 PCR is an indicator for infection 
associated with urological procedures. 
2. The presence of circulating pathogen DNA correlates with host immune and physiological 
response supporting the notion that antibiotic prophylaxis is important in urological 
procedures. 
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Participant recruitment  
 
All eligible participants were identified through either urology outpatient clinics, elective or 
emergency admission under the Salford Royal Urology team. Potential participants were 
provided with a written information sheet giving details of the research question and protocol 
and were given at least 24 hours to decide on whether to participate in the study. The 
potential eligible participants had been formally listed for either ureteroscopy or percutaneous 
nephrolithotomy. Informed written consent were obtained from eligible participant (REC 
reference 10/H1016/135) 
The inclusion criteria were that all participants were older than 16, were due to be listed for 
the aforementioned urological procedures for ureteric stones and showed capacity to consent 
to participation in the study. Interpreter facilities were made available for potential 
participants who were unable to understand English.  
Study design 
 
The following diagram shows the study design for this proof of concept study and highlights 
when microbiological and immunochemical sampling occurred. In addition, the figure shows 
when data was collected on the physiological status of the patient during the pre procedure, 
peri procedure and post procedure phases (Figure 7).  
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Figure 7 Study Design 
 
Induction of 
anaesthesia 
T1 
 
T2 
 
T3 
 
T5 
Post op 
observation 
2 week notes 
review 
Measured parameters 
Blood pressure, Heart 
rate, Temperature, 
Clinical interventions 
Timing of PCR 
sampling (T) 
Intra – operative 
events 
Post – operative 
events 
Measured parameters  
Blood pressure, Heart 
rate, Temperature, 
Clinical interventions  
Blood cultures taken 
 
T4 
EWS 0 - 6 hrs 
EWS 6 – 12 hrs  
EWS 24 – 48hrs  
EWS 12 – 24hrs 
Operative  
stages 
Interventions and 
observations 
Figure 8 - Study design 
Figure 7 – The figure highlights the pivotal time points within the study 
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Blood sampling  
From each participant, 5 mls of blood was taken at five distinct referenced time points for 
analysis of pathogen DNA by SeptiFast
®
 PCR assay. These five specific time points 
represented times during the procedure which were proposed as the times when there would 
be an increased likelihood of pathogen DNA material being shed into the participant's blood 
stream. An additional 20mls of blood was taken at the point of maximal urological 
instrumentation use (time point T3). This time point was postulated as the time where 
maximal pathogen DNA shedding would likely occur and this 20mls was used for blood 
culture analysis. The timing schedule for blood sampling for all participants in the study is 
shown below (Table 5).  
Table 5 – Timing schedule for blood sampling for RT-PCR analysis 
 
Patient                                 Timing (t) 
   T1 T2 T3 T4 T5 
A Induction At visualisation of 
renal stone 
During laser On stenting  Post op in 
recovery 
B Induction Puncture lithotripsy Suturing patient 
for closure at end 
of operation 
Post op in 
recovery 
C Induction At visualisation of 
renal stone  
During laser On stenting Post op in 
recovery 
D Induction At visualisation of 
renal stone 
During laser On stenting Post op in 
recovery 
E Induction At visualisation of 
renal stone 
During laser On stenting Post op in 
recovery 
F Induction At visualisation of 
renal stone 
During laser On stenting Post op in 
recovery 
G Induction At visualisation of 
renal stone 
During laser On stenting Post op in 
recovery 
H Induction At visualisation of 
renal stone 
During laser On stenting Post op in 
recovery 
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I Induction At visualisation of 
renal stone 
Just after laser 
and basketing 
Post stent 
insertion 
Post op in 
recovery 
J Induction As first removing 
papillae 
Mid – removing 
papillae 
Not done* Not done* 
K Induction Puncture Lithotripsy Suturing patient 
for closure at end 
of operation 
Post op in 
recovery 
L Induction At visualisation of 
renal stone 
During laser At stenting  Post op in 
recovery 
 
All patients had blood sampled at the point of anaesthesia as time point T1. In the cohort, 2 
patients had PCNL and the other 10 patients had ureteroscopy procedures, so the T2 - T4 
time points were different in the PCNL patients from the ureteroscopy patients. In planning 
the study, there was a clear discussion with our urology team who proposed that the 
inflammatory response generated by PCNL was likely to be similar to the inflammatory 
response seen in the ureterscopy procedures (personal communications with Mr Chris Betts, 
consultant urologist). 
The blood samples were transported immediately to the on-site Biomedical Research Facility 
laboratories for further processing. One aliquot of blood (~2.5ml) was collected in EDTA 
tubes and stored at -80
o
C for subsequent analysis of pathogen DNA by SeptiFast
®
 multiplex 
PCR. A second aliquot (~2.5ml) was collected in lithium-heparin tubes and plasma prepared 
by centrifuging the blood at 1500g for 10 minutes at 40
o
C. The plasma was removed from the 
cell pellet using a plastic pastette and stored in ~1ml aliquots at -80
o
C for analysis of 
immune-inflammatory markers, IL-6 and IL-10 by ELISA.  
Data collection  
For all study participants, a series of basic demographic information was obtained from our 
electronic patient record systems including age, sex and urological diagnosis. At each blood 
56 
 
sampling time point, the following parameters were recorded: blood pressure, temperature, 
pulse rate and clinical observations such as use of inotropic drugs and intravenous fluid 
administration. Post operative, the early warning score (EWS) for each participant over a 48 
hour period post procedure was recorded.  
The EWS tool is used in Salford Royal Foundation Trust to assess the degree of illness of 
patients. It is based on data derived from four physiological readings (systolic blood pressure, 
heart rate, respiratory rate, body temperature) and one observation (level of consciousness, 
AVPU). The resulting observations are compared to a normal range to generate a single 
composite score with the higher the score the higher the level of medical care or risk of death. 
This data was obtained by review of the electronic patient records (EPR) used in Salford 
Royal Foundation trust. A subsequent review of the EPR system was done to see if any of the 
study participants were readmitted within two weeks from the date of their urological 
procedure. In addition, urine culture and stone debris results sent on the day of the 
participant’s procedures were obtained and analysed. If no urine culture results from the day 
of the procedure were obtained a retrospectively review for any recent mid-stream urine 
results was performed. 
Laboratory analyses 
Analysis of pathogen DNA by SeptiFast
®
 PCR assay  
SeptiFast
®
 is a CE - marked assay for detection of a panel of bacterial and fungal pathogens 
in blood. The organisms covered by SeptiFast
®
 represents > 95% of pathogens commonly 
found in healthcare-associated blood stream infections (Table 6). The assay involves steps for 
extraction of pathogen DNA and pathogen DNA analysis by real - time and was performed 
according to the manufacturer's detailed protocol.   
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Table 6 - SeptiFast
®
 Pathogen Detection Panel 
 
Gram negative Gram positive Fungi 
Escherichia coli 
Klebsiella (pneumoniae/oxytoca) 
Serratia marcescens 
Enterobacter (cloacae/aerogenes) 
Proteus mirabilis 
Pseudomonas aeruginosa 
Acinetobacter baumannii 
Stenotrophomonas maltophila 
Staphylococcus aureus 
CoNS 
Staphylococci * 
Streptococcus pneumoniae  
Streptococcus spp ** 
Enterococcus faecium 
Enterococcus faecalis 
Candida albicans 
Candida tropicalis 
Candida parapsilosis 
Candida krusei 
Candida glabrata 
Aspergillus fumigatus 
                      *S.epidermis, S. haemolytics ** S.pyogenes. S.agalactae, S.mitis 
 
 Pathogen DNA extraction from blood 
In order to initiate DNA extraction, whole blood samples were mixed on a bottle roller for 30 
minutes. 1.5ml of each whole blood specimen was placed in SeptiFast
®
 Lys Kit MGRAD 
tubes and subjected to mechanical lysis with ceramic beads in a MagNALyzer
®
 instrument 
(Roche Diagnostics GmbH, Mannheim, Germany) for70 sec at 7000 rpm and left to stand in 
the MagNALyzer for 10 min.  
SeptiFast
®
 preparation M Grade kit (Roche Diagnostics GmbH, Mannheim, Germany) was 
used to extract the DNA using the protocol provided by the manufacturers. 1ml of the lysed 
specimen was vortexed with 150ul of proteinase K and an internal control (10ul; IC) and 
1500ul of chaotropic lysis buffer (50% guanidinium, Tris-HCL buffer, thiocyanate and 20% 
Triton X-100) were then added.  
To promote the release of the DNA, this mixture was incubated for 15 min at 56°C with 
gentle mixing at 500rpm. Following mixing with the binding buffer, the extract was 
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transferred onto spin columns designed to adsorb genomic DNA to the glass fibre matrix. 
Unbound substances were removed by washing the spin columns sequentially with 1.8ml 
inhibition removal buffer (containing 50% guanidinium HCL, 40% ethanol and Tris-HCl 
buffer) and 1.6ml wash buffer (containing 0.2% sodium chloride, Tris-HCl buffer and 80% 
ethanol). Finally, the adsorbed genomic DNA was eluted into1.5ml DNA-free reagent tubes 
by incubation with 300µl  of preheated (70°C) elution buffer (containing Tris-HCl) for 5 min 
followed by centrifugation for 2 min at 4200xg. This extract contained pathogen DNA which 
was then assayed by SeptiFast
®
. 
SeptiFast
®
 real-time PCR of pathogen DNA  
Real-time PCR was carried out in 100µl glass capillary tubes  using the LightCycler
®
2.0 
instrument. Three capillary tubes were used per specimen for detection of Gram positive 
bacteria, Gram negative bacteria and Fungi with appropriate controls. 50µl of ready-to-use 
master mix (Roche Diagnostics) was added to 50µl of the target DNA.  
The process of PCR amplification begins with a Pre-UNG incubation cycle at 40°C for 5 
min. This cycle is carried out for the activation of Uracil-N-glycosylate that recognizes and 
catalyses the destruction of DNA strands containing deoxyuridine, but not DNA 
deoxythymidine. Since, PCR products contain uracil while genomic DNA contains 
thymidine; this procedure reduces the risk of carry-over contamination in the assay. 
PCR was initiated by a denaturation cycle at 95°C for 10 min followed by two amplification 
programs (1-2) and a single melting curve profile (3). 
1. 15 cycles of denaturation at 95°C for 15 sec, annealing at 58°C for 50 cycles and 
extension at 72°C for 40 sec. 
2. 30 cycles of denaturation at 95°C for 15 sec, annealing at 58°C for 50 sec and 
extension at 72°C for 40 sec. 
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3. Denaturation at 95°C for 60 sec, annealing at 40°C for 60 sec and melting at 80°C at a 
temperature change rate of 0.1°C/sec. 
SeptiFast
®
- Identification of pathogen species and controls.   
The measured fluorescence (emitted during the annealing phase when the fluorescent probe 
hybridizes to the PCR amplicons) in four different detection channels was detected.  
The assay is provided with specialised software (SeptiFast
®
 Identification Software, SIS) 
which facilitates automated identification of species and controls by analysing the melting 
temperatures of the amplicons produced and a report for the pathogen status for each sample 
is obtained. The analysis protocol adopted by SeptiFast
®
 is based on the study by Lehmann et 
al who elegantly showed that melting centre analysis permits rapid simultaneous detection of 
25 different microorganisms using wide signal-to-signal melting peak differences (Lehmann 
et al, 2008). The specific melting temperatures for the PCR products and probes derived from 
the different organisms are shown in Figure 8 overleaf (Lehmann et al, 2008). 
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Figure 8 - Distribution of melting temperature and respective detection channels for all 
microorganisms and internal control in the SeptiFast
®
 assay (Lehmann et al, 2008) 
Figure 8 – Distribution of melting temperature (Tm) and respective detection 
channels for all microorganism and internal controls.  A= Gram negative bacteria; 
B= Gram positive bacteria; C=Fungi  
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Cytokine analysis 
 
IL-6 ELISA 
 
IL-6 was measured using a Pelikine compact human sandwich enzyme-linked 
immunosorbent assay (ELISA) kit (Mast Diagnostics M1916). All solutions were made up 
according to the manufacturer’s instructions.  
A ninety six well plate was coated with the monoclonal antibody anti-human IL-6 coat 
antibody diluted 1:100 in coating buffer and 100µl was added to each well. The covered plate 
was incubated at room temperature (18-250) overnight. The plate was washed five times with 
PBS using an automatic plate washer. 200µl of blocking buffer was added to each well and 
the plate was incubated at room temperature for one hour. A standard curve was prepared as 
per the specification sheet, and the plate was washed five times with wash buffer (PBS with 
0.005% TWEEN 20).  
The substrate blank wells were left empty and 100µl of standards and diluted samples were 
added to the appropriate wells. The plate was re-covered and incubated at room temperature 
for one hour, with continuous shaking at 700rpm. Biotinylated antibody was diluted 1:100 in 
working-strength high performance ELISA dilution buffer (HPE). The plate was washed five 
times in wash buffer, the substrate blank wells were left empty and 100µl diluted biotinylated 
antibody was added to the remaining wells. The plate was re-covered and again incubated at 
room temperature for one hour, whilst being shaken at 700rpm. The streptavidin-horseradish 
peroxidise (HRP) conjugate was diluted 1:10 000 in working strength HPE dilution buffer. 
The plate was washed a further five times in wash buffer, and 100µl streptavidin-HRP 
conjugate was added to all wells except the substrate blank wells. 
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The covered plate was incubated at room temperature for 30 minutes, whilst being shaken at 
700rpm. A suitable volume of TMB (Invitrogen 00-2023) was brought to room temperature 
ensuring that it was not exposed to light. A stop solution (1.8M sulphuric acid) was also 
prepared. The plate was re-washed five times and 100µl substrate was added to all wells. The 
plate was incubated in the dark at room temperature for 30 minutes, whilst being shaken. 
100µl of stop solution was added to all wells and the plate was read at 450nm using a Victor 
multi-label counter (Wallac, Milton Keynes, UK). The cytokine concentrations were 
determined using a four parameter curve fit algorithm (Delta Soft analysis software, 
BioMetallics Inc, Princeton, NJ). 
Figure 9 - The principle of sandwich ELISA (adapted from www.lenico.com) 
 
IL-10 ELISA 
 
 
Figure 9 –.An enzyme-linked immunosorbent assay (ELISA) is typically performed to 
detect the presence and / or amount of a target protein 
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IL-10 ELISA 
IL-10 was measured using a Pelikine compact human sandwich ELISA kit (Mast Diagnostics 
M1910), following the same protocol as used for IL-6 (Fig 9). The sandwich ELISA process 
initially starts with a plate being coated with capture antibody. Blocking buffer is added to 
block remaining protein-binding sites on plate. A sample is added to plate and any antigen 
present is bound by the capture antibody. A washing stage follows to remove any non-
binding antigen. The next step usually involves a labelling reagent which can be a labelled 
detection antibody which when added to the plate binds to any antigen present and triggers an 
enzymatic reaction to produce a detectable product for analysis.  
Statistical analysis  
 
In looking for an association between the detection of circulating pathogen DNA and 
interleukin levels, I used a simple unpaired t test at each time point to compare those with 
positive and negative pathogen DNA at each time point.  
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SeptiFast
®
 assay coverage and historic data on positive cultures 
 
Before commencing the study, it was necessary to validate the use of the SeptiFast
®
 assay in 
this study population by ensuring that it detects those organisms typically associated with 
bacteriuria after stone extraction at Salford Royal Foundation Trust (SRFT). The urological 
services at SRFT have collected a database containing clinical infection and microbiological 
data for all patients who underwent renal stone removal surgery from 2004 – 2011. The 
SeptiFast
®
 assay was designed to detect and identify 25 bacterial and fungal species that 
make up to greater than 90% of the pathogens causing bloodstream infections in critical care. 
By comparing these 25 microorganisms against those found in the SRFT urology database, it 
was possible to ascertain whether SeptiFast
® 
was the right research tool to use to test the 
hypotheses. 
Table 7 - List of positive organism growth from mid-stream urine sample from all 
patients who underwent renal stone removal surgery at Salford Royal Foundation Trust 
from 2004 – 2011. 
Gram negative bacteria Gram positive bacteria  Fungi 
Stenotrophomonas.maltophila Staphylococcal.sp  
Pseudomonas.sp Enterococcus.sp  
Escherischia.coli   
Proteus.sp   
 
The above table (Table 7) shows the list of positive organism growth from mid-stream urine 
samples from all patients who underwent renal stone removal surgery in the trust from 2004 – 
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2011. Comparing with the SeptiFast
®
 Pathogen Detection Panel (Table 5), it can be seen that 
the SeptiFast
® 
assay's coverage of organisms, has 100% overlap with the organisms detected 
via mid-stream urine results from the historical data compiled by urology services of SRFT. 
Study Population 
 
Twelve patients were consented for participation in the study. These 12 patients all 
underwent a urological procedure between 27 September 2011 and 14 November 2011. Ten 
patients (83%) underwent ureteroscopy with laser treatment to renal stones followed by 
ureteric stent insertion and two of 12 patients underwent PCNL. The median age of the study 
population was 54.5 years (interquartile range 24 - 61 yrs.).  
The study population comprised of five male patients and seven female patients. For the 
purpose of this proof of concept study, we assume that similar inflammatory reactions occur 
with both described urological intervention as both procedures are using instrumentation in 
removal of renal stones. The basic demographics data for the 12 patients included in the study 
are shown in the following table (Table 8) 
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Table 8 - Patient demographic and operation detail 
Patient identification Age Gender  Operation 
A 77 M Left ureteroscopy and 
laser to ureteric stone, 
basket extraction and 
insertion of stent 
B 20 F Left PCNL
 
C 59 M Left ureteroscopy and 
laser to ureteric stone 
extraction, insertion of 
stent  
D 62 M Right ureteroscopy and 
laser to stone, insertion 
of stent 
E 61 F Left ureteroscopy and 
laser to ureteric stone, 
insertion of stent 
F 50 M Left ureteroscopy and 
laser to ureteric stone, 
basket extraction of 
fragments, insertion of 
stent 
G 61 F Right ureteroscopy, 
removal of stent, laser 
to stone, insertion of 
stent 
H 24 F Left ureteroscopy and 
laser to ureteric stone, 
basket extraction of 
fragments, insertion of 
stent 
I 75 F Right ureteroscopy and 
laser to stone, basket 
extraction of fragments 
and washout, insertion 
of stent 
J 25 F Left ureteroscopy and 
laser to stone 
K 20 F Left PCNL
 
L 32 M Left ureteroscopy, 
removal of stent, 
basket extraction of 
fragments and laser to 
stone, insertion of stent 
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Pathogen species identified by SeptiFast
®
 assay and blood culture  
 
Using the SeptiFast
®
 assay, the detection of a PCR signal was either classified as positive 
(signal present) or negative (signal absent). A positive blood culture result occurred in one 
out of the 12 patients (9%). The organism detected was the yeast, Candida glabrata. 
A total of six patients (50% of cohort) returned a positive signal for the presence of 
circulating pathogen DNA. It can be argued from the data that the absence of PCR signal for 
pathogen DNA is likely to be an indicator of the absence of infection. In the case of patient J, 
there was a positive signal for circulating pathogen DNA and positive blood culture (Table 
8). Post operatively, Patient J was transferred to a critical care setting for severe urosepsis. 
Five out of the six patients with a positive signal from SeptiFast
®
 assay had a detectable 
signal at a single time point. One patient had a positive signal at anaesthetic induction 
(Patient H, T1), another at the time of maximal instrumentation (Patient J, T3) whilst two 
separate patients had positive signals in post recovery (Patients F & L, T5). Patient I was the 
only patient to elicit positive DNA signals at two separate time points in the procedure (T3 
and T4 respectively). These results are all highlighted in the next the table overleaf (Table 9). 
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Table 9 - Detection of pathogen DNA signal RT - PCR on blood samples at different 
time points 
Patient Frequency 
of sampling 
for PCR 
analysis 
detected (n) 
Blood 
Culture 
positive 
PCR 
signal 
T1 
PCR 
signal 
 T2 
PCR 
signal 
 T3 
PCR 
signal  
T4 
PCR 
signal  
T5 
A 5 No Negative Negative Negative Negative Negative 
B 5 No Negative Negative  Negative Negative Negative 
C 5 No Negative Negative Negative  Negative  Negative 
D 5 No Negative Negative Negative Negative Negative 
E 5 No Negative Negative Negative Negative Negative 
F 5 No Negative Negative Negative Negative Positive 
G 5 No Negative Negative Negative Negative Negative 
H 5 No Positive Negative Negative Negative Negative 
I 5 No Negative Negative Positive Positive  Negative 
J 3 Yes Negative Negative Positive Not 
applicable 
Not 
applicable 
K 5 No Negative Positive Negative Negative Negative 
L 5 No Negative Negative Negative Negative Positive 
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PCR positive signal patients vs. PCR negative signal patients  
The background characteristics between those where the SeptiFast
®
 PCR assay detected 
circulating DNA compared to those with a negative signal from the PCR assay was 
compared. The PCR negative group were our control group in the study (Table 10). 
Table 10 - Characteristic of PCR positive patients vs. PCR negative patients 
 
Characteristic PCR signal detection 
 PCR positive PCR negative 
Female : Male 4 : 2 3 : 3 
Median age, range (yrs.) 28.5 years  (20 - 75) 61 years, (20 - 77) 
Percutaneous 
nephrolithotomy ( PCNL) 
1 /6 1/6 
Vasopressor use in 
procedure 
1/6 2/6 
Gentamicin administered 
at T1 
6/6
a 
6/6 
Tazocin administered at T1 1/6
b 
1/6
b 
Augmentin administered at 
T1 
2/6
 
0/6 
Mean LOS for readmission 
directly related to 
infectious complication of 
procedures 
7 days 4 days 
 
 
Key: 
a - Patient J received 300mg compared to 120mg given to the other 11 patients. 
b - given to PCNL patients 
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There are more females than males in the PCR positive signal group compared to the PCR 
negative group. The mean age in the positive signal group was 38 years compared to 57 years 
in the negative signal group. The proportion of PCNL to ureteroscopy/ laser treatment/ 
ureteric stent insertion procedures was identical in both groups. 
In both groups all patients received gentamicin. All patients received 120 mg gentamicin, 
apart from patient J who received 300 mg gentamicin and was clinically unwell throughout 
the procedure. In the two patients who had PCNL, each were also given two doses of 
Piperacillin/ tazobactam 4.5 grams as prophylaxis. Piperacillin/ tazobactam is a combination 
broad spectrum antibiotic containing the extended-spectrum penicillin antibiotic piperacillin 
and the β-lactamase inhibitor tazobactam. In addition, two of those in the PCR positive group 
were also given a dose of Augmentin 1.2g in the T1 stage. These results highlight that the 
antibiotic strategies used in these procedures are not fixed and universal.  
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Relationship between pathogen isolate and clinical outcome 
In the group with a positive signal detected on PCR, three patients were admitted with 
infective episodes within 30 days of their initial procedures (table 11), 
Table 11 - Correlation between PCR positivity and clinical outcome 
 
Patient Organism detected 
by blood culture 
Organism detected 
by SeptiFast® 
analysis 
Post - operative 
event 
F Nil detected Streptococcal sp 
S.pneumoniae 
Had subsequent 
EWSL. 2 weeks later 
stent removal then 
Readmitted next day 
with clinical episode 
of urosepsis - within 
30 days of initial 
procedure 
H Not performed K.pneumoniae / 
oxytoca 
No clinical episodes 
of urosepsis 
I Nil detected E. Faecalis No clinical episodes 
of urosepsis 
J Candida glabrata Candida glabrata Clinical episode of 
urosepsis – stent 
removal, post op 
admission  
K Nil detected E.coli Subsequent 
admission with 
pyelonephritis – 
required readmission  
L Nil detected S.aureus No clinical episodes 
of urosepsis 
 
In the PCR positive group, Patient F was readmitted with urosepsis. After the patient's initial 
interventional procedure, the patient underwent a non-invasive urological procedure for stone 
removal, Extracorporeal Shock Wave Lithotripsy (EWSL) and subsequently had the stent 
removed. The day after removal of stent the patient was admitted with urosepsis.  
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Urine samples taken at the time of the EWSL and on admission with urosepsis showed only 
pyuria. If the urine culture had grown streptococcal sp and/or S.pneumoniae, it would have 
provided evidence that the interventional procedure may have directly contributed to the 
episode of urosepsis.  
Within the PCR positive group, patient K was admitted with a clinical diagnosis of 
pyelonephritis directly related to the urological intervention. This patient was readmitted 12 
days post procedure. The patient had a positive PCR signal for E.coli but on readmission had 
no growth in blood culture. Urine cultures from readmission episodes were positive for skin 
flora and pyuria.  
The third patient, patient J, had a clinical diagnosis of urosepsis. The patient developed septic 
shock post procedure and required admission to intensive care unit. In this patient, Candida 
glabrata was detected on both SeptiFast
®
 assay and blood cultures. Regarding the length of 
stay seen, the total extra in-patient bed days attributed to infection in the PCR positive group 
was 14 days with the mean stay in the two patients with an infection episode being seven 
days. 
In the PCR negative group (table 12 overleaf), one patient was re-admitted for urosepsis 12 
days post procedure. Urine was sent from two separate sites, a urostomy sample and a sample 
from the patient's urinary catheter. E.coli was grown from a sample sent from urostomy 
whilst the urinary catheter sample showed pyuria only. In the PCR negative group, the length 
of stay in the only patient with a clinical episode of infection was four days. These results 
suggest that PCR positive patients have a poorer clinical outcome regarding increased 
frequency of infections and longer length of stay.  
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Table 12 - Correlation between PCR negativity and clinical outcome 
 
Patient Organism detected 
by blood culture 
Organism detected 
by SeptiFast® 
analysis 
Post - operative 
event 
A Nil detected Nil detected No clinical episode 
of urosepsis 
B Nil detected Nil detected Clinical episode of 
urosepsis - antibiotics 
and subsequent 
repeat PCNL. 
C Nil detected Nil detected No clinical episode 
of urosepsis 
D Nil detected Nil detected No clinical episode 
of urosepsis 
E Nil detected  Nil detected No clinical episode 
of urosepsis 
G Nil detected Nil detected No clinical episode 
of urosepsis 
    
 
Analysis of circulating IL-6 and IL-10 levels  
Immunochemical analysis was performed to establish if there was any detectable relationship 
between the presence of pathogen DNA and the level of plasma IL-6 and IL-10 in patients 
undergoing these interventional urological procedures. Plasma IL - 6 and plasma IL - 10 
levels were measured in the T1 - T5 samples and direct comparisons were made between the 
PCR  positive group and PCR negative group (Fig 10).  
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Figure 10 - Mean IL – 6 and IL-10 in PCR positive and PCR negative patients 
 
 
 
The mean level of IL - 6 in PCR - positive group was higher by a factor of five at all time 
points compared to the level found in PCR - negative group. This effect was statistically 
significant (p<0.05) at all time points except for T5 (Figure 12) A different pattern was 
observed with IL-10 (Figure 12). There was no statistic difference (p > 0.05) between the 
Figure 10  - This figure clearly shows that at each time point the detected level of IL – 6 is 
higher in those with a positive signal compared to those where no signal was detected. 
This pattern was not seen with IL – 10. 
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mean plasma levels of IL - 10 between the PCR - positive and PCR - negative group at any 
time points, although there was some qualitative evidence of higher levels at T3 and T4 in the 
PCR - positive groups.  
From these results, there seems to be an association between the detection of circulating 
pathogen DNA and elevated pro inflammatory cytokine levels. The results demonstrate a 
likely link between the presence of circulating pathogen DNA and the host immune response 
in this study population. 
Pathogen detection and physiological response 
All patients had bedside observations and this helped to assess if there was an association 
between the peri procedure observations such as temperature, pulse and blood pressure 
(markers of physiological response) and PCR positivity. Blood pressure was expressed as the 
mean arterial blood pressure (MAP). The MAP is a measure of the perfusion pressure to vital 
organs of the body. 
MAP is derived from the formula: 
Mean arterial pressure = diastolic blood pressure + 0.33 (systolic blood pressure - 
diastolic blood pressure) in mmHg 
The measured pulse rate is a measure of the heart's response during the procedures and is 
expressed in beats per minute. There was no clear pattern in the physiological responses seen 
in the PCR positive or PCR negative group. There seems to be no clear difference in the 
witnessed variation in the MAP across the time points when comparing those who were PCR 
positive with those who were PCR negative (Fig 11 and 12). When the mean MAP across 
each study group is compared at all time points, there was no clear difference seen (Fig 13). 
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Figure 11 - Variations of mean arterial blood pressures in PCR negative group 
 
 
 
 
Figure 12 - Variation of mean arterial blood pressure in PCR positive group 
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Figure 11 – In the 6 patients who were PCR signal negative, there is no clear variation in MAP 
with the time points. 
Figure 12 – The PCR signal positive patients have differing MAPs across the different time 
points with no clear pattern of change across the timepoints for each patient.  
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Figure 13 - Comparison of the variation of mean MAP between PCR positive patient 
group and PCR negative patient group 
 
 
The cardiovascular system response can be assessed by both MAP and heart rates. In the PCR 
negative group, there was a generalised high starting pulse rate at T1 amongst the PCR 
negative patients with a lower pulse rate recorded at T5 in these patients but not to a point of 
bradycardia (pulse rate below 60 beats per minute). 
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Figure 13 – The mean MAP at each time point showed no difference between patients with a 
positive signal and those patients  with no signal detected. 
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Figure 14 - Variations in pulse rate in PCR negative group 
 
 
In the PCR positive group, 3/6 patients exhibited a rise in their pulse rate with two patients 
exhibiting tachycardia (pulse rate higher than 100 beats per minute). However, there was no 
uniform or observed pattern to the change in pulse rate for either the PCR positive or PCR 
negative patients (Fig 16). This is highlighted when, from these results, there is no marked 
difference between the blood pressure and pulse responses seen between the PCR positive 
and the PCR negative group through the procedures. 
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Figure14 – There was no consistent pulse variations in those who do not have DNA detected 
by PCR across the 5 time points.  
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Figure 15 - Variations in pulse rate in PCR positive groups 
 
 
Figure 16 - A comparison of the variation between mean pulse rate between PCR 
negative patients and PCR positive patients 
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Figure 15 – In the 6 patients who had a PCR positive signal, there was no observed pattern 
across the patients in the response of their pulse rates across the different time points.  
Figure 16 – This figure shows that there is no difference between the mean pulse rates at 
different time points between the two groups 
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Case specific findings - PCR positive patients 
Case J had a positive blood culture and positive DNA signal at time point T3 and 
subsequently had a significant rise in temperature and pulse rate in recovery room post 
procedure. The patient became more unwell and deteriorated leading to sample at T4 and T5 
not being taken. This patient progressed rapidly from a SIRS response to septic shock, and 
required admission to intensive care for organ support. Case J needed aggressive fluid 
resuscitation throughout the procedure and had a total length of stay in hospital of eight days. 
Case F had Streptococcal sp and S pneumoniae detected with the SeptiFast
®
 assay. This 
patient experienced a steady drop in blood pressure across the five time points associated 
with a similar drop in pulse rate as well but no recorded bradycardia (pulse rate less than 60 
beats per minute). Case H had a positive signal for K.pneumoniae /oxytoca by the SeptiFast
®
 
assay. Case F was administered metaraminol at T1 stage. It is a well-known phenomenon for 
blood pressure to be low due to the anaesthetics. Metaraminol is an alpha 1 adrenergic 
receptor agonist and is used by anaesthetists for this clinical indication. 
Case specific findings - PCR negative patients 
Patient A was hemodynamically unstable during the procedure. Patient A had a tachycardia 
(120 beats per minute) and a reduced MAP (56.7). At each of the first four time points, the 
patient received vasopressor therapy - ephedrine (T1 and T3) and metaraminol (T2 and T4). 
This patient, however, had no post operative complications and did not require hospital 
admission. The patient was both PCR and blood culture negative. This hemodynamic 
instability was not associated with an inflammatory response to a pathogen.  
Patient B had a clinical episode of urosepsis and was readmitted for IV antibiotics treatment 
12 days after the procedure. The patient had six units of blood loss through the procedure and 
required four litres of intravenous fluids. No vasopressor medication was administered during 
the procedure and the patient’s total length of stay on readmission was four days. 
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 Stone composition and pathogen detection 
 
There is evidence in the literature that stones of certain compositions, such as struvite stones 
are associated with pathogens such as Klebsiella and Proteus. (Tseng et al, 2011)  
These urease producing bacteria are well-recognised predisposing factors for stone formation 
(Tseng et al 2011). In our study there was a clear association between the detection of 
circulating pathogen DNA and the presence of calcium oxalate stones (Table 13). There was 
no clear evidence of any growth from the stone particles sent for analysis (Table 13). With 
the study population being so small, care needs to be taken from drawing conclusions and 
larger study would further prove if there is an association between stone composition and 
pathogen detection.  
 
Table 13 - Stone composition and organism detection 
 
Patient  Stone composition 
(percentage) 
Record of 
culture from 
stone 
Organism 
detected by 
blood culture 
Organism detected 
by SeptiFast
®
 
analysis  
A Uric acid (99%) No Nil detected Nil detected  
B Calcium phosphate 
(47%) Magnesium 
ammonium phosphate 
(53%) 
No Nil detected  Nil detected 
D Calcium oxalate 
(98%) 
No Nil detected  Nil detected  
E Calcium oxalate 
monohydrate (96%)  
No Nil detected  Nil detected 
F Calcium oxalate 
(98%) 
No Nil detected  Streptococcal sp 
S.pneumoniae 
I Calcium oxalate 
(97%) 
No Nil detected  E. Faecalis 
L Calcium oxalate 
(21%) Urate (79%) 
No Nil detected  S.aureus 
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CHAPTER 4 
 DISCUSSION 
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Background of the study  
This is the first proof of concept study to propose that urological procedures involving 
instrumentation could be a reproducible model to study pathogenaemia in man. If there was a 
better understanding of the role pathogens play in triggering the host immune response, we 
would be able to further our knowledge on the pathogenesis of infection and sepsis. Sepsis is 
clinically deﬁned when a patient shows at least two of the criteria for systemic inflammatory 
response (SIRS) with evidence of systemic infection (Mancini et al, 2010). 
The systemic inflammatory response (SIRS) is activated in patients in response to either a 
non-infectious (e.g. tissue injury. trauma) or an infectious aetiology; however, it is not 
uncommon for both forms of aetiology to co-exist. The difficulty from a diagnostic point of 
view is determining when the inflammatory response is caused by infection (i.e. sepsis).  
Blood cultures are the current gold standard for microbial detection in the blood stream. 
Blood culture analysis is often unreliable, particularly where patients have received 
antimicrobial therapy. Recent advances in molecular diagnostics allow the measurement of 
DNA from pathogens in clinical samples (i.e. blood). These approaches are less likely to be 
affected by antibiotic use and may have great benefit in the diagnostic process. 
Currently, the relationship between circulating pathogen DNA, the presence of infection and 
the impact on the systemic inflammatory response is not fully understood. There have been a 
number of both animal and human models of sepsis described in the literature. In this thesis, I 
propose that an easily reproducible  model for exploring the relationship between circulating 
pathogen DNA and the subsequent inflammatory response could be urological procedures 
involving instrumentation.  
It was initially thought that, endourological surgery were considered clean contaminated 
procedures and did not require antibiotic coverage. A clean-contaminated surgical site is seen 
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when the operative procedure enters into a colonized viscus or cavity of the body, but under 
elective and controlled circumstances.  However, evidence in the literature dating back 
decades shows that urological instrumentation is associated with increased incidence of 
urinary tract infection and bacteraemia (Alsaywid et al, 2013).  
Infections and urosepsis is one of the most common complications seen in urological 
procedures. The rate of infection complication in all urological procedures in the literature is 
as high as 12 - 14 % in the literature (Bjerklund et al 2007). Following ureteroscopy, the 
reported incidences of UTI range between 3.9% and 25%. (Rao et al, 1991, Puppo et al, 1991, 
Hendrickx et al, 1999).  
A number of studies have previously highlighted the significant inflammatory response in 
patients undergoing endourological manipulations for urinary stones. A frequently referenced 
study on this was published by Rao et al in 1991 (Rao et al, 1991). In an effort to predict 
septicaemia following endourological manipulation for stones in the upper urinary tract, 117 
patients were studied and classified according to the procedure performed ( Rao et al, 1991). 
In this study, fever was  used as a proxy for infection and 74% of the PCNL patients in their 
study developed post-operative fever; however, only 41% had endotoxemia. The only patient 
in the Rao's study to develop septic shock had a PCNL. 
Antibiotic prophylaxis is commonly used perioperative in urological surgery and procedures 
to alleviate the occurrence of infection. Antibiotic prophylaxis aims to prevent healthcare- 
associated infections that result from diagnostic and therapeutic procedures (Grabe et al, 
2012). I have highlighted the prevalence and incidence of infection and sepsis in those 
undergoing endourological procedures however regarding evidence of countering infection 
with antibiotic prophylaxis, there is no clear-cut evidence that exists on the use of antibiotic 
prophylaxis in this population (Knopf et al, 2003, Fourcade et al, 1990). 
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 In this study, ureteroscopy and PCNL are the two urological interventions which may be 
useful in vivo models for investigating pathogenaemia in man. If this model shows that there 
is a relationship the presence of a detectable level of circulating pathogen DNA and a 
witnessed immune and physiological response, this would suggest a possible beneficial need 
for the use of prophylactic antibiotics . In this study, there was evidence of a relationship 
between the levels of cytokines particularly IL - 6 and the presence of circulating pathogen 
DNA , however in this study the only patient to develop severe sepsis (to prompt an 
admission to ICU) did not receive antimicrobial to cover the causative organism i.e. fungi. As 
a result of our study I  therefore propose that a randomised controlled trial on antimicrobial 
prophylaxis in this population is warranted.  
Current international guidelines state that it is important to distinguish urological 
interventions into low-risk procedures (e.g. simple diagnostic and distal stone treatment) and 
higher-risk procedures (e.g. treatment of proximal impacted stones and intrarenal 
interventions) when considering prophylactic antibiotics (Grabe et al, 2012). In higher-risk 
procedures, there would be more of an indication to use antibiotic prophylaxis.  
In this study, all patients received some form of antibiotic prophylaxis; however, the 
antibiotic regimen was variable 25% of the study population (3/12 patients) went on to 
develop an infective episode despite the use of prophylactic antibiotics. However, it is hard to 
provide strong arguments against prophylactic antibiotics in a study of this size with 
difference in the choice of antibiotics, doses and time of administration of antibiotics.  
In a recent worldwide study, (Gutierrez et al, 2013) 5803 consecutive PCNL patients were 
enrolled from 96 centres over 12 months to participate in the PCNL Global Study. The 
presence of a post-operative fever of ≥38.5°C was used as a proxy for infection in this study 
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and the main finding was that a10% of PCNL-treated patients developed fever in the post-
operative period despite receiving antibiotic prophylaxis. 
In this proof of concept study, my aim was:- 
1. To appraise the presence and significance of blood borne microorganisms that may 
appear in patients during interventional urological surgery involving urinary tract 
instrumentation by (blood culture and by multiplex real time polymerase chain 
reaction assay (SeptiFast
®
 Roche). 
2. To appraise the host immune response and physiological response in the study 
population to the presence of circulating pathogen DNA and if this provides evidence 
for the use of antibiotics prophylactically in these patients.  
On-going research using PCR technology in an in vivo human model of pathogenaemia could 
help determine if PCR technology has a role in the detection of circulating pathogen DNA in 
infective and septic patients. PCR technology could supersede the current gold standard of 
pathogen detection in blood in clinical settings and provide rapid detection of pathogen 
regardless of whether antibiotics have been administered.  
 Key findings of the study 
 
The key findings from the study are that the SeptiFast
®
 assay had broad pathogen coverage 
for this study population. In the group of patients with circulating pathogen DNA detected by 
SeptiFast
®
, there was a clear immune response elicited (elevated cytokine levels) but no 
witnessed physiological response in this group, when compared with patients with no 
detectable circulating pathogen DNA. 
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SeptiFast
®
 - Role in circulating pathogen DNA detection in infection ? 
 
The SeptiFast
®
 assay was chosen as the assay to test the study hypotheses. The SeptiFast
®
 
assay has been available longer than any other molecular-based tests. SeptiFast
®
 uses real-
time PCR in a non-quantitative mode to identify ten bacteria at the species level, several more 
at the genus level, as well as five Candida species and Aspergillus fumigates. This assay 
reportedly identifies the 25 organisms that account for more than 90% of the culturable 
pathogens associated with sepsis (Ecker et al, 2010). 
Prior to commencing this study, a review of the collected historical data on urological 
procedures as Salford Royal Foundation Trust urology services show that the SeptiFast
® 
assay has complete coverage of all the pathogens present in urine cultures commonly seen in 
the urology patients treated at Salford Royal. This confirms the suitability of this potential 
diagnostic tool in this study population. Notably, the SeptiFast
®
 assay did not detect any 
circulating pathogen DNA from a species not normally seen in this clinical setting.  
In our study, 1 patient (9%) had a positive growth from blood culture and the organism 
detected was Candida glabrata. This figure is well within the range for rate of positive 
cultures associated with urological surgery in the literature (Knopf et al, 2003, Dogan et al, 
2002). This patient was admitted to intensive care for organ support due to urosepsis. In a 
number of papers looking specifically at those with urosepsis after endourological 
intervention for stones, blood cultures tend not to be positive and sepsis rates are 0.25 - 1.5 % 
(Demirtas et al, 2012, Dogan et al, 2002). Interestingly, with studies looking specifically at 
PCNL, between 0.3 and 9.3% of patients can develop potentially life-threatening sepsis 
(Michel et al, 2007, Draga et al, 2009). In this proof of concept study, we have assumed that 
PCNL and ureteroscopy produce similar results and further work would need to be done to 
establish if this assumption is valid.  
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In our thesis, there is a low level of blood culture positivity compared to PCR positivity from 
the SeptiFast
®
 assay and there are a number of possible explanations for this observation. A 
proposed reason for this finding could relate to the administration of antibiotics pre procedure 
which can affect the detection of pathogen by blood cultures. In our study, out of the four 
patients in the study who had infective and / or septic episodes post procedure, 50% were 
PCR positive  blood culture negative, 25% were PCR positive blood culture positive. Blood 
cultures are reported to be negative in more than 50% of the cases where true bacterial or 
fungal sepsis is believed to exist (Ecker et al, 2010). A theoretical explanation between the 
difference in circulating pathogen DNA detection (by SeptiFast
®
) and intact pathogen 
detection (by blood cultures) could relate directly to the urological procedure. In these 
endourological procedures, the use of instrumentation could lead to the introduction of 
fragments of pathogen DNA particles into the blood stream rather than intact pathogen. 
SeptiFast
®
 - A place in clinical practice? 
There are no described studies in the literature on the use of the SeptiFast
®
 assay in the 
setting of urological surgery. There have been a number of studies looking at the use of 
SeptiFast
® 
assay in other clinical settings. In a recent Danish study (Westh et al, 2009) 
SeptiFast
®
 was compared directly against blood cultures in patients with suspected bacterial 
and fungal sepsis. The aim of the study was to observe if non viable pathogen detection by 
SeptiFast
®
 would aid in the clinical decision making process. The group postulated that one 
advantage of PCR assays over blood cultures is that DNA based detection systems can detect 
pathogens causing sepsis at the time of sampling if they are viable or non viable. 
558 samples from 359 patients were evaluated. The rate of positivity was 17% from blood 
cultures (BC) and 26% from SeptiFast
® 
assay. 96 microorganisms were isolated with BC, and 
186 microorganisms were identified with SeptiFast
®
; 231 microorganisms were found by 
combining the two tests. Of the 96 isolates identified with blood culture, 22 isolates were 
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considered to be contaminants. Of the remaining 74 non-contaminant BC isolates available 
for comparison with SeptiFast
®
, 50 were identified as a species identical to the species 
identified with SeptiFast
®
 in the paired sample. Of the remaining 24 BC isolates for which 
the species, identified in the BC, could not be detected in the paired Septifast
®
 sample. 18 BC 
isolates were identified as a species included in the SeptiFast
® 
masterlist, and six blood 
culture isolate were not organism detected by SeptiFast
® 
. With SeptiFast
®
, 186 
microorganisms were identified, 12 of which were considered to be contaminants. Of the 174 
clinically relevant microorganisms identified with Septifast
®
, 50 (29%) were detected by BC. 
More than half of the remaining microorganisms identified with SeptiFast
®
 (but not isolated 
after BC) were also found in routine cultures of other relevant samples taken from the 
patients. 
Dierkes et al (Dierkes et al, 2009) performed a retrospective analysis of PCR results on the 
clinical management of patients with presumed sepsis. Of the 101 blood samples from 77 
patients with presumed sepsis, 39 samples had pathogens identified from either the use of 
blood cultures or the SeptiFast
®
 assay. From the samples, 63 (62%) yielded concordant 
negative results, 14 (13 %) concordant positive and 9 (9%) were blood culture positive only. 
In 14 (13%) samples pathogen was detected only by PCR assay, resulting in adjustment to 
therapy in five patients. In three samples a treatment adjustment would have been made 
earlier resulting in a total of 8 adjustment in all 101 samples (8%). In this single centre study 
with small number, the group have suggested that rapid molecular diagnostic tests may lead 
to a higher rate of early adequate antibiotic therapy in approximately 8% of patients with 
suspected sepsis. This could have had a potential therapeutic impact on clinical outcomes.  
The SeptiFast
®
 assay ability for pathogen detection has also been used in onco-
haematological patients (Mancini et al, 2008). These patients are susceptible to neutropenia. 
The term 'neutropenia' describes low levels of neutrophils in the blood. Neutrophils are 
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important in fighting bacterial infections. Among the 103 blood samples, 35 (34 %) samples 
were positive by at least one of the two methods. Twenty-one (20.4 %) samples were positive 
by blood culture and 34 (33 %) with SeptiFast®. The analysis of concordance evidenced a low 
correlation between the two approaches. When comparing the six hour turnaround time for 
the SeptiFast
®
 assay with blood cultures, even in the two observed cases of fast-growing 
Escherichia coli, a mean of 10 h of incubation was needed, with definitive identification after 
an additional 36 h (Mancini et al, 2008). As evident from these three separate studies, there is 
potential in the utilisation of the SeptiFast
®
 assay in the management of infection. In this 
thesis, one of our main hypotheses was to ascertain if the detection of circulating DNA by the 
SeptiFast
®
 assay was an indicator of infection.  
In this study, two out of the three patients who went on to have an infective or septic episode 
only had an organism detected by the SeptiFast
®
 assay alone and not by blood cultures. Only 
one patient who was PCR signal and blood culture negative, went on to have a clinical 
episode of urosepsis. Half of the patients in the study with a positive signal for an organism 
detected by the SeptiFast
®
 assay did not go on to develop an infective or septic episode. In 
this small study, there was a low level of blood culture positivity and I was unable to do a 
direct assessment of concordance between PCR assay and blood cultures as diagnostic tools. 
In the study, the one patient who had a fulminant fungal septicaemia gave a positive signal 
via the SeptiFast
®
 assay and had a positive BC.  
In this study, the presence of detectable DNA seem to stimulate an inflammatory response. 
The clinical relevance of this is that potentially we have a technology which will greatly 
speed up the identification of pathogenic organisms and faciltate the prompt and targeted 
treatment in patients with sepsis and infection. 
92 
 
Using blood culture as a reference ‘gold standard’ to compare molecular methods has been 
shown to be problematic in the literature. It is well recognised that blood culture fails to 
identify more than 50% of the cases of sepsis believed to be caused by bacteria or fungi based 
on clinical and other criteria (Ecker et al, 2010). In most studies, SeptiFast
®
 consistently 
identified more positive specimens than blood culture methods (Pletz et al, 2011) and this 
was seen in this study. An obvious limitation of the SeptiFast
®
 as a diagnostic tool is that the 
assay does not provide information about antimicrobial susceptibilities of the organisms 
detected. 
In this study, half of the cases with positive PCR signal can be classed as 'false' positive 
results. The definition of PCR ‘false’ positives is those cases in which the presence of 
pathogen DNA is associated with no growth in simultaneous blood cultures. In this study, our 
controls were those who were negative for DNA signal. The lack of normal control group 
makes it difficult to assess the SeptiFast
® 
assay with respect to false positive outcomes. There 
has however been a recent study (Warhurst et al, 2015) which has set out to determine the 
accuracy of SeptiFast
® 
real-time PCR for the detection of health care associated BSI against 
standard microbiological culture. 
Of 1006 new patient episodes of systemic inflammation in 853 patients, 922 (92%) met the 
inclusion criteria and provided sufficient information for analysis. Adult patients had been 
exposed to a median of 8 days (interquartile range 4–16 days) of hospital care, had high 
levels of organ support activities and recent antibiotic exposure. SeptiFast
®
 real-time PCR, 
when compared with culture-proven bloodstream infection at species/genus level, had better 
specificity (85.8%, 95% CI 83.3% to 88.1%) than sensitivity (50%, 95% CI 39.1% to 60.8%). 
When compared with pooled diagnostic metrics derived from their systematic review, their 
clinical study revealed lower test accuracy of SeptiFast
®
 real-time PCR, mainly as a result of 
low diagnostic sensitivity. There was a low prevalence of BC-proven pathogens in these 
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patients (9.2%, 95% CI 7.4% to 11.2%) such that the post-test probabilities of both a positive 
(26.3%, 95% CI 19.8% to 33.7%) and a negative SeptiFast
®
 test (5.6%, 95% CI 4.1% to 
7.4%) indicate the potential limitations of this technology in the diagnosis of bloodstream 
infection. Using this analysis approach, the sensitivity of the SeptiFast
®
 test was low but also 
appeared significantly better than BC. Blood samples identified as positive by either culture 
or SeptiFast
®
 real-time PCR were associated with a high probability (> 95%) of infection, 
indicating higher diagnostic rule-in utility than was apparent using conventional analyses of 
diagnostic accuracy. In my study, all of the urology patients were subject to sterile injury, had 
evidence of systemic inflammation and had prophylactic antibiotics administered so the data 
from the aforementioned study (Warhurst et al, 2015) data could be applied to our population.  
The presence of false positive patients poses more questions than answers regarding the 
detecting of circulating DNA by the SeptiFast
®
 assay as a potential indicator of infection. 
Avolio et al (Avolio et al, 2010) compared traditional blood cultures with SeptiFast
®
 in cases 
suspected to have blood borne infection. There were 10 patients who had an organism 
detected by SeptiFast
®
 but not by blood culture that subsequently had microbiology 
confirmation from other sites. It would be important, therefore, to differentiate between DNA 
associated with intact pathogens from free pathogen DNA detected by PCR, if pathogen 
DNAemia is to be a marker of infection. PCR analysis may be a sensitive method of 
detecting pathogen DNA released in to circulation at levels which would:  
1. Not be detected by sampling volumes obtained for blood cultures; 
2. From sites with restricted or poor blood flow. 
Importantly, PCR assays are not affected by antimicrobials given (Ecker et al, 2010, Mancini 
et al, 2010). 
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A separate issue raised by false positive cases is that, presently, we cannot ascertain through 
the assays if the circulating pathogen DNA detected is associated with viable bacteria rather 
than non-viable bacteria destroyed by host immune system +/- antimicrobial therapy. So we 
cannot, in this study, definitely say that the detected circulating pathogen in the case which 
was PCR signal positive and blood culture negative was acting as a pathogen. 
In the study amongst all the patients who were PCR signal positive, a positive signal for 
pathogen DNA was detected at all time points. However, it was often noted that it was only 
present transiently in each of the six PCR positive cases. There are a number of likely 
possibilities for these findings. Firstly, there is the possibility that pathogen DNA is only 
found fleetingly in circulation. A second viable explanation is that circulating pathogen DNA 
levels may be low or close to limits of detection by the SeptiFast
®
 assay so that in some of 
the cases DNA may not have been detected even though present. Thirdly, sampling may be 
an issue and a larger study population may help to explain this.  
SeptiFast
®
 consistently identified more positive specimens than blood culture methods; 
however, the seminal paper on SeptiFast
®
 (Lehmann et al, 2008) showed that culture 
consistently identified some organisms that were not identified by SeptiFast
®
. There are a 
number of possible explanations such as the larger volume of blood analysed by culture and 
the lower limit of SeptiFast
®
 detection of approximately 3–30 CFU/ml. Ideally, we would 
want to use as sensitive a PCR assay as possible and, presently, the most sensitive is the 
SeptiFast
®
 assay. 
Circulating pathogen DNA and the immune response 
In this study, there was a strong correlation between the detection of circulating pathogen 
DNA and increased level of IL - 6. These results suggest that in these urology patients there 
is a positive association between the presence of circulating pathogen DNA and the witnessed 
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immune response. However, there was no direct association between circulating DNA and 
the physiological response in these patients. 
It has been shown that bacterial - derived short DNA fragments are able to stimulate immune 
cells to promote the release of IL-6 from human mono nuclear cells (Schindler et al, 2004). In 
this study, we have shown an association between the presence of circulating pathogen DNA 
and increased IL- 6 detected levels during urological procedures in this study population. In 
our study, cytokine levels were reviewed over the period of the procedure and in post 
operation (Mokart et al, 2002). In this study, serial blood samples were collected from 30 
consecutive patients for determination of serum cytokine levels. Healthy volunteers were 
used as the control group. Eleven patients developed no complications (group 1), 14 
developed sepsis or severe sepsis (group 2), and five developed septic shock (group 3). 
After operation IL-6 levels in group 1 were increased in comparison with day 0 but 
normalized with time, suggesting that surgical trauma induced the immediate and temporary 
postoperative increase in IL-6 concentration. However, on day 1, patients in groups 2 and 3 
had IL-6 levels that were respectively, two and six times higher than those in group 1 
patients. In addition, they remained high during the course of the study. These high levels of 
IL-6 were independently associated with postoperative septic events and correlated with post- 
operative morbidity (length of ICU stay and duration of mechanical ventilation). As septic 
events always occurred after day 2 the group it suggested that, IL-6 is probably an early 
indicator of post-operative infection following the trauma of major oncological surgery 
(Mokart et al, 2002). It would be interesting to use our study population to confirm these 
findings.  
The findings in this thesis suggest that the detectable presence of pathogen DNA could 
stimulate an inflammatory response. In the literature, there have been advances in our 
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knowledge on how the cells of our immune system detect microbial pathogens. The ability of 
the host's immune system to sense nucleic acid is one such mechanism which has been 
extensively studied. For detecting microbial DNA, toll - like receptor 6 (TLR6) in endosomes 
and numerous cytoplasmic DNA binding proteins have been discovered (Holm et al, 2013). 
Toll-like receptors (TLRs) are a class of pattern recognition molecules that play a unique 
function in the innate immune system. This system is the first line of defence against 
microorganisms that initiate cellular signal in response to pathogen-associated molecular 
patterns (PAMPs) and induce expression of genes involved in the inflammatory process, 
therefore, it plays a crucial role initiating and directing the adaptive immune system 
(Jahantigh et al, 2013). 
Ten functional TLR members (TLR1–TLR13) have been identified in humans. TLR9, an 
endosomal localized receptor on B cells, plasmacytoid dendritic cells (pDCs), and 
monocytes/ macrophages, recognizes unmethylated nucleic acid motifs, especially Cytosine-
phosphate-Guanine motifs, in bacterial DNA and it is one of the most important receptors in 
the initiation of protective immunity against intracellular pathogens by activation signalling 
cascade of intracellular receptor signalling (Jahantigh et al, 2013). From our study, we 
detected similar DNA levels in the patients with a positive signal from the SeptiFast
®
 study; 
however, we do not currently know whether this level of pathogen DNA could activate the 
TLR9.  
The urology patient: Host response, sepsis and antibiotic prophylaxis  
This study is not the first to look at the host inflammatory response and sepsis in urology 
patients. Rao et al’s (Rao et al 1991) study is one of the most cited studies in urology that 
looked directly at systemic inflammatory responses and sepsis in patients undergoing 
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urological manipulation. In the individuals in this study who had PCNL, despite use of a 
prophylactic antibiotic, postoperative bacteraemia and fever are reported as 37% and 74%.  
Antibiotic prophylaxis aims to prevent healthcare associated infections that result from 
diagnostic and therapeutic procedures. Antibiotic prophylaxis is only one of several measures 
to prevent infections and can never compensate for poor hygiene and operative technique. 
The principle of antibiotic prophylaxis is to provide protection to the patient with creating an 
environment to promote antibiotic resistance (Grabe et al, 2012). Unfortunately, the benefit 
of antibiotic prophylaxis for most modern urological procedures has not yet been established 
by well-designed intervention studies (Grabe et al, 2012). Antibiotic prophylaxis in urology 
has been controversial for many years. In the literature regarding PCNL case studies, there is 
conflicting evidence for the role of prophylactic antibiotics s evidence in PCNL procedures.  
Charton et al (Charton et al, 1986) reviewed 126 cases of percutaneous extraction of renal 
stones by PCNL that no major septic complication was observed without prophylaxis. Only 
10% of the patients were exposed to fever and 35% had bacteriuria. Mariappan et al 
(Mariappan et al, 2006) presented results showing that treating patients who have dilated 
pelvicalyceal systems and / or stones of ≥ 20 mm before PCNL with ciprofloxacin 250 mg 
twice daily for 1 week significantly reduces the risk of upper UTI and urosepsis. Eighteen of 
46 (39%) patients in the control group developed SIRS, whereas only 7 of 52 (13.4%) 
patients in the treatment group developed SIRS. Mariappan's group reported that one-week 
administration of ciprofloxacin prophylaxis decreased positivity of pelvicalyceal culture by 
three times, stone culture positivity by two times, and risk of developing SIRS by  three 
times.  
In this study, circulating pathogen DNA is definitely seen to stimulate a significant 
inflammatory response in this urology population. Within the study, a quarter of our patients 
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went on to develop an infective episode despite the use of prophylactic antibiotics. So, in this 
proof of concept study, even though we have been able to appraise the host immune response 
to the presence of circulating pathogen DNA the study cannot put forward evidence for the 
use of antibiotics prophylactically in his population. This study has not provided concrete 
evidence to support the use of prophylactic antibiotics in this group but has stimulated 
enough questions to suggest the need to design a RCT in this population. The model may be a 
useful system to explore this but we would need to look in a larger study population with set 
antibiotic protocol regarding antibiotic use, dose administered and time of antibiotic 
administration during the procedure.  
It is widely appreciated that the presence of urinary stones is a risk factor for infectious 
complication in urological procedures and is associated with increased bacterial load (Grabe 
et al, 2012). There has also been literature which has looked at the association of the 
composition of the stones and infection (Tseng et al, 2011). In our study, there was no 
association between stone composition and the circulating pathogen DNAemia. 
Strength and weakness of the study 
The major strength of this proof of concept study is that even with this small number of 
patients we have been able to address the hypotheses above and have provided results which 
suggest that this study should be scaled up in regards to study number to find if these results 
are reproducible in larger cohorts. Compared to animal study, this in vivo study gives us 
results in the clinical setting which is a strength of the study.  
There were limitations in this study. In obtaining the ethics for this study, our study size was 
targeted to a small number of 12. The assay cost are high and not in routine use and it was 
decided when obtaining our ethics approval that a first in man proof of concept study of this 
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size was deemed acceptable. However, with such a small number, it can be difficult to 
ascertain the true significance from the data obtained in our study.  
In our group of 12, there were two patients who had PCNL, not out of design, but due to the  
nature of the cases encountered. Prior to the study commencing discussions were had with the 
urology department (personal communication with Mr Chris Betts, consultant urologist) and 
it was felt that the similar surgical insult between the two urological procedures would likely 
produce a comparable inflammatory response. If the study was scaled up, it would be ideal to 
compare these procedures head to head to prove this postulation.  
In regards to other weaknesses to the study, it would have been ideal to compare urinary 
samples for growth to see if there was any concordance with Septifast
@
 assay. The fact that a 
complete database of results was not present on all patients slightly weakens the findings 
presented. 
Future work 
This proof of study has set up the potential for further work. 
It is important to take this work forward by using the same study design but to recruit enough 
patients so the study is well powered to: 
1. Show that the findings in this study are reproducible; 
2. Have sufficient numbers to show if the observed findings are truly statistically significant. 
Hopefully, in future studies we could test if there is concordance between the detection of 
circulating pathogen DNA and other microbiological samples (e.g. mid-stream urine samples 
peri - operatively or pathogens in stone debris). In future testing, it would be good to explore 
the use of prophylactic antibiotics in this model by having patients split into an arm having a 
prophylactic antibiotics pre procedure and an arm which does not receive prophylactic 
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antibiotics. It would show if there is any effect of the antibiotics on pathogen detection by 
blood culture and SeptiFast
®
 and if the immune response effects seen are different. This 
would add further evidence on the role of prophylactic antibiotics in this population.  
Conclusion  
This was a proof of concept study looking to see if urology patients having instrumental stone 
removal procedures could potentially be an in vivo model for exploring pathogenaemia in 
humans. The data from this study provides novel evidence that presence of pathogen 
DNAemia correlates with an increased systemic inflammatory response. This may be a useful 
model system for understanding the role of pathogen DNA in triggering inflammatory 
responses to infection in man. Additionally, further studies using this model may address the 
issue of the role of antibiotic prophylaxis in endourological procedures. However, larger 
studies are needed for this work to progress further.  
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